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ABSTRACT OF DISSERTATION

ROLE OF SULFIREDOXIN INTERACTING PROTEINS IN LUNG CANCER
DEVELOPMENT
Sulfiredoxin (Srx) is an antioxidant enzyme that can be induced by oxidative
stress. It promotes oncogenic phenotypes of cell proliferation, colony formation,
migration, and metastasis in lung, skin and colon cancers. Srx reduces the overoxidation
of 2-cysteine peroxiredoxins in cells, in addition to its role of removing glutathione
modification from several proteins. In this study, I explored additional physiological
functions of Srx in lung cancer through studying its interacting proteins. Protein disulfide
isomerase (PDI) family members, thioredoxin domain containing protein 5 (TXNDC5)
and protein disulfide isomerase family A member 6 (PDIA6), were detected to interact
with Srx. Therefore, I proposed that TXNDC5 and PDIA6 are important for the oncogenic
phenotypes of Srx in lung cancer.
In chapter one, I presented background information about the role of Srx as an
antioxidant enzyme in cancer. I also explained the functional significance of PDIs as
oxidoreductase and chaperones in cells. In chapter two, I verified the SrxTXNDC5/PDIA6 interaction in HEK293T and A549 cells by co-immunoprecipitation and
other assays. In TXNDC5 and PDIA6, the N-terminal thioredoxin-like domain (D1) is
determined to be the main platform for interaction with Srx. The Srx-TXNDC5 interaction
was enhanced by H2O2 treatment in A549 cells. Srx was determined to localize in the
endoplasmic reticulum (ER) of A549 cells along with TXNDC5 and PDIA6. This
localization was confirmed by both subcellular fractionation and immunofluorescence
imaging experiments. In chapter three I focused on studying the physiological function of
Srx interacting proteins in the ER. A549 subcellular fractionation results showed that
TXNDC5 facilitates Srx retention in the ER. Moreover, TXNDC5 and Srx were found to
participate in chaperone activities in lung cancer. Both proteins contributed in the
refolding of heat-shock induced protein aggregates. In addition, TXNDC5 and PDIA6
were found to enhance the protein refolding in response to H2O2 treatment. Conversely,
Srx appeared to have an inhibitory effect on protein folding under same treatment
conditions. Downregulation of Srx, TXNDC5, or PDIA6 significantly reduced cell viability
in response to tunicamycin treatment. TXNDC5 knockdown decreased the time required
for the splicing of X-box binding protein-1 (XBP-1). In either knockdown Srx or TXNDC5
cells, there was an observable decrease in the expression of GRP78 and the splicing of
spliced XBP-1. These results suggest a possible role of Srx in unfolded protein response
signaling. TXNDC5 and PDIA6, similar to Srx, contribute to the proliferation, anchorage
independent colony formation and migration of lung cancer cells.

In this dissertation I concluded that Srx TXNDC5, and PDIA6 proteins participate
in oxidative protein folding in lung cancer. Srx and TXNDC5 can modulate unfolded
protein response (UPR) sensor activation and growth inhibition. Furthermore, TXNDC5
and PDIA6 can promote tumorigenesis of lung cancer cells. Therefore, the molecular
interaction of Srx with TXNDC5/PDIA6 has the potential to be used as novel therapeutic
targets for lung cancer treatment.

KEYWORDS: Sulfiredoxin, thioredoxin domain containing protein 5, protein disulfide
isomerase A isoform 6, interaction, function
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CHAPTER ONE
INTRODUCTION
1.1 Background
Lung cancer is the second most common cancer in men and women. Lung and
bronchus cancer is the main cause of cancer death in the United States. It comprises
approximately 27% of estimated cancer deaths (Siegel et al., 2016). The 5-year survival
rate is only 16%. Among the major factors for lung cancer high fatality rate are poor
early detection, difficulty of treatment, tumor recurrence and metastasis. The lifetime risk
of lung cancer development is 1.3–1.4% in both male and female in non-smokers. The
risk increases to 17% in male smokers and 13% in female smokers, respectively
(Durham & Adcock, 2015; Zhang et al, 2016; Torre et al, 2016; de Groot et al, 2012).
Cancer originates from the cells lining airways of bronchial lung tissues. Tumors arising
from squamous cells and basal epithelial cells are termed non-small-cell carcinomas
(NSCLC). Tumors consisting of undifferentiated smaller-than-normal cells are termed
small-cell carcinomas (SCLC). NCSLCs are subdivided to adenocarcinoma, large-cell
carcinoma, and squamous cell carcinoma, which account for 40%, 10%, and 30% of
lung cancer cases, respectively. The remaining 20% of all cases are diagnosed as
SCLC (Gadgeel et al, 2012; Durham & Adcock, 2015). For normal lung cells to become
tumor cells, series of genetic mutations must occur, that lead to the formation of benign
tumors. Additional genetic modifications cause the mutated cells to acquire metastatic
and invasive behaviors, triggering them to take on the characteristic features of cancer
cells (Cooper, 2005).
Among these verified changes are increases in cellular levels of reactive oxygen
species (ROS). This feature is accompanied by enhanced competence of antioxidant
systems in the cells (Kim et al, 2015; Watson et al, 2016). Cellular peroxidases,
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including 2-cysteine containing peroxiredoxins (2-Cys Prxs), are among the antioxidant
systems that contribute to the development of lung cancer (Kwon et al, 2015; Kim et al;
2011). For instance, PrxI and PrxIV have been found to enhance colony formation and
migration in vivo metastasis of lung cancer cells (Jaing et al, 2014; Kwon et al, 2015). In
general, Prxs strictly regulate H2O2 levels. 2-cys Prx reduce H2O2 to generate H2O. At
the same time, Prxs oxidize other protein substrates, such as protein disulfide isomerase
family members, to generate disulfide bonds (Ramming & Appenzeller-Herzog, 2013;
Kakihana et al, 2011). H2O2 oxidizes a highly nucleophilic active cysteine residue called
peroxidative cysteine (Cp) in 2-Cys Prx to sulfenic acid. This Cp is then attacked by
another cysteine residue, resolving cysteine (CR), which is present on the surface of a
second 2-Cys Prx protein; to generate a disulfide linked Prx homodimer (Pace et al,
2013; Zhu et al, 2014). In the presence of high concentrations of H2O2, the sulfenic acid
at the Cp site can be overoxidized to generate sulfinic acid (and sulfonic acid) before the
CR can form the disulfide bond. If unresolved, 2-Cys Prx loses its peroxidative activity
and acquire additional features, such as the ability to form disulfide bonds independent
stacks of decamers that possess chaperone activity (Pace et al, 2013; Schulte et al,
2011).
Hyperoxidation can stabilize these decameric forms of PrxI, II, and IV in
cooperation with other proteins. The protein disulfide isomerase family members,
predominantly, thioredoxin-domain-containing protein 5 (TXNDC5), protein disulfide
isomerase family A member 6 (PDIA6), and protein disulfide isomerase (PDIA1), are
reported to interact directly with overoxidized 2-Cys Prx, particularly PrxII and PrxIV.
These PDI members act to stabilize the decameric structure of PrxIV (Pace et al, 2013;
Sato et al, 2014; Zhu et al, 2014). TXNDC5 and PDIA6 interact with PrxIV in Hela cells
to facilitate rapid formation of disulfide bonds in newly synthesized protein substrates in
2

a process of oxidative protein folding. PDIA1 functions at a slower pace to proofread and
fold the nascent protein substrate. Thus high affinity of PDI members for overoxidized 2Cys Prx shifts H2O2 signaling in cells (Pace et al, 2013; Sato et al, 2014).
As an adaptive mechanism against this prolonged overoxidation of Prxs, cells
have adapted recycling machinery for reducing overoxidized Cp residue from sulfinic acid
to sulfenic acid through differential expression of sulfiredoxin (Srx) enzyme, on the
expense of ATP. Srx transfers ϒ-phosphate of ATP to Cp sulfinic acid modification on 2Cys Prxs, to produce sulfinic phosphoryl ester. Glutathione and thioredoxin counterparts
reduce sulfinic phosphoryl ester to sulfenic acid (Biteau et al, 2003; Woo et al, 2003;
Chang et al, 2004). The presence of Srx appears to be necessary to maintain the
oxidative stress balance in cancer. Srx inhibition results in oxidative stress-induced
mitochondrial damage and caspase cascade activation that lead to apoptosis in lung
adenocarcinoma cells (Kim et al, 2016; Baek et al, 2012). Beside H2O2 mediated
signaling, Srx de-glutathionylates several proteins, including PrxI, protein tyrosine
phosphatase 1B, and actin. Meanwhile, Srx itself is not glutathionylated since there is
only one cysteine residue. In this term, Srx is known to be the first protein to function
specifically in reductive de-glutathionylation (Findlay et al, 2006; Grek et al, 2013).
Srx in cancer
Srx is expressed under oxidative stress conditions. Srx expression is under the
control of transcription factors nuclear erythroid 2-related factor 2(Nrf2) and activator
protein 1 (AP-1) (Soriano et al, 2008; Ramesh et al, 2014). Nrf2 is required for Srx
protein expression because cells that do not have Nrf2 do not express Srx. In normal
lung cells, there is minimal expression of Srx. However, significantly higher expression
level was observed in lung cancer, particularly in adenocarcinoma and squamous cell
carcinoma (Merikallio et al, 2012; Wei et al, 2011). In fact, the Srx-PrxIV axis was found
3

to promote cancer progression through the modulation of phosphokinase signaling
components. Srx is required for the activation of MEK1/2, and promotes the proliferation,
colony formation, and metastasis of cancer cells. Srx and PrxIV are required in AP-1/
matrix metallopeptidase 9 (MMP-9) axis activation, which can enhance tumorgenesis
(Wei et al, 2011).
Additionally, Srx expression is upregulated in squamous cell carcinoma, basal
cell carcinoma, sweat gland carcinoma, and melanoma in human skin relative to controls
(Wu et al, 2014; Wei et al, 2008). As indicated by TUNEL assay, Srx-depleted tumor
cells showed higher levels of apoptosis and there were fewer papillomas in mouse skin.
Treating mouse skin with 12-O-tetradecanoylphorbol 13-acetate (TPA) prompted Srx
expression via the activation of JNK and MAKP signaling pathways (Wu et al, 2014). Srx
was also found to be upregulated in poorly differentiated colorectal cancers. And
downregulation of Srx led to decreased cancer cell colony formation and cell migration in
vitro. Srx depletion also reduced tumor formation and metastasis of colon cancer in
mouse models. Srx limits the acetylation of tyrosine (K1037) on epidermal growth factor
receptor (EGFR) thus increasing EGFR phosphorylation and the activity of the EGFRMAPK signaling pathway (Jiang et al, 2015; Wei et al, 2013).
Srx interacts with S100 calcium-binding protein A4 (S100A4) protein to modulate its
interaction with non-muscle myosin IIA protein (NMIIA) in lung cancer cell line. S100A4
and NMIIA form a complex that bind reversibly with actin filament. Srx regulate Ca2+
binding to S100A4 in a redox-mediated manner. Thus, Srx redox activities are believed
to regulated motility, migration and adhesion of lung cancer cells (Bowers et al, 2012;
Conti et al, 2008).
Out of six isoforms of Prxs (PrxI-VI), Srx can only reduce the sulfinic acid
modification in four isoforms, 2-Cys PrxI–IV. The affinity of Srx is different for various 2Cys Prxs. When GST fusion protein of Srx was expressed in Hela cells,
4

immunoprecipitation of H2O2 treated cell lysate indicated that Srx had more affinity
toward PrxI and PrxII than toward PrxIII and PrxIV (Woo et al, 2005). In addition, the
only cysteine residue of Srx, Cys99, which is responsible in the formation of thiosulfinate
with protein substrates, did not affect Srx-2-Cys Prx interaction when mutated to serine
(Woo et al, 2005). Immunoprecipitation and mass spectrometry results from Wei et al
(2011) confirmed that Srx interacts with Prx I–IV when Flag-tagged Srx expressed in
HEK293T and A549 cell lines. However, Srx was found to have more affinity toward
PrxIV. The same study was also first to recognize the interaction between Srx with
TXNDC5 and PDIA6 proteins in HEK293T and in A549 cells (Wei et al, 2011). TXNDC5
and PDIA6 belong to the same family of PDI enzymes. So far, the significance of SrxTXNDC5/PDIA6 interactions has not yet been characterized.

The PDI family
The redox system in cells is generally categorized as reducing and hypoxic in the
cytosol, oxidizing and normoxic in the extracellular milieu, and oxidizing in the ER
(Jordan et al, 2005; Essex, 2009). Due to this variation in redox state, cells have
developed many signaling pathways to regulate redox reactions. Redox reactions are
implicated in many cellular processes, including stabilization of proteins through
generation and rearrangement of disulfide bonds. PDIs are group of 21 enzymes that
have a central role in thiol-disulfide reactions in cells. Structurally, most PDIs share one
or more thioredoxin-like domains, cysteine-X-X-cysteine (CXXC), and ER retention
signal (Figure 1.1). Hence, PDIs are believed to play a pivotal role in the biogenesis of
approximately one third of proteins destined to enter the secretory pathway (Hatahet &
Ruddock, et al 2009). PDIA1 was the first PDI to be discovered in 1963. It is a multifunctional oxidoreductase that participates in nascent protein folding in different cellular
compartments, including the mitochondria, plasma membrane, and ER (Kozlov et al,
5

2010). PDIA1 is involved in processes such as disulfide bond formation, reduction,
isomerization, and disulfide exchange reactions (Figure 1.2). Disulfides generated in PDI
originate from several sources, including endoplasmic reticulum oxidoreductin-1alpha
(Ero1alpha), 2-Cys Prxs, vitamin K epoxide reductase (VKER), glutathione peroxidase
(GPX) 7 and 8, and dehydroascorbate reduction to ascorbate pathways (Bulleid &
Ellgaard, 2011; Lu & Holmgern, 2014; Bulleid, 2012; Shepherd et al, 2014). H2O2 can
directly oxidize PDIs to generate disulfide bonds.
These pathways function as oxidants to transfer electrons to oxidize active-site
cysteine residues on PDI. PDIs in turn oxidize newly synthesized protein substrates in
the ER to ensure synthesis of physiologically functional native protein substrates (Figure
1.3). Oxidation of cysteine residue during disulfide bond formation is accompanied by
oxidative protein folding. In this form, electrons are transferred from the reduced
substrate to the PDIs active sites (Zito et al, 2010; Lu & Holmgren, 2014). Hence, PDIs
are considered indispensable enzymes for providing maturation and structural stability
for substrates (Sato et al, 2013; Lu & Holmgren, 2014). Several PDIs, particularly PDIA1
and PDIA6, have been found to take part in reduction and isomerization of receptor
proteins. A related point to consider is that nascent protein substrates can also fold to
their native form in pathways independent of PDI proteins. The quiescin sulfhydryl
oxidase (QSOX) pathway can be considered one instance of this (Figure 1.4).
The enzymatic activity of PDI family members depends on four main structural
features. The first feature is number and sequence of active site CXXC motifs. For
instance, PDIA19 (ERdj5) has four thioredoxin-like domains, three of which have CXPC
motifs function as thiol-disulfide reductants. ERdj5 reduces thioredoxin-like domain in
PDIA6. The reduced PDIA6 interacts with unfolded protein response (UPR) sensor
inositol-requiring enzyme 1 (IRE1) in the ER lumen (Oka et al, 2015). PDIs with CXHC
thioredoxin like sequence are shown to act as efficient thiol-disulfide oxidants. For
6

instance, Ero1 selectively oxidizes PDIA1, which has two active site CGHC domains with
two b domains, whereas Ero1 has less activity toward TXNDC5, which contains three
CGHC folds and no b domains. PrxIV is shown to preferentially oxidize TXNDC5 and
PDIA6 relative to other protein PDIs (Sato et al, 2013).
The second factor in determination of PDI enzymatic activity is the presence of
certain amino acid residues in PDI structure to modulate pKa of CXXC motif. Local
movement of arginine residue is found to lower the pKa of active CXXC domain (Lappi et
al, 2004). Arginine residues determine the time required for the client protein to bind to
the active site in oxidation and isomerization reactions. The importance of this residue
has been validated in PDIA1 PDIA3, PDIA4, and PDIA6 proteins (Lappi et al, 2004;
Ellgaard & Ruddock, 2005). Another important factor in regulating CXXC activity is the
presence of glutamic acid-lysine pairs in proximity to the thioredoxin like domain.
Glutamic acid acts as an electron acceptor, which facilitates exchange of protons
between PDIs and client protein substrates. A PDIA1 and PDIA3 oxidative activity is
regulated by this residue (Ellgaard & Ruddock, 2005).
The fourth factor is the presence of high-affinity substrate binding pocket, b
domain. The presence of b domain has been shown to be required for isomerization
activity in PDIs. For instance, the thioredoxin like domain and b domain containing
PDIA1 and PDIA3, are established to have oxidase and isomerase activities, whereas
TXNDC5, and TMX3 (Thioredoxin-Related Transmembrane Protein 3), that lack the b
domain, are proposed to be proficient in oxidation but not isomerization. PDI enzymes
lacking thioredoxin-like domain, such as PDIA8, PDIA9, and TMX2, are proposed to be
indirectly involved in disulfide bond exchange reactions (Bastos-Aristizabal, et al., 2014;
Ellgaard & Ruddock, 2005). The variation in thiol-disulfide reactions and the selectivity of
different PDIs toward different substrates suggests the presence of a hierarchy among
PDIs toward these reactions. In fact, it has been shown that PDI members can exchange
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disulfide with each other. In addition, certain PDIs facilitate thiol-exchange reactions with
other PDIs. For instance, PDIA1 and TXNDC5 were found to be conduits for oxidation of
other PDIs via the Ero1 oxidation pathway. Meanwhile, ERdj5 is the conduit for reduction
reactions (Oka et al, 2015).

Figure 1.1. Domain architecture of the protein disulfide isomerase (PDI) family.
Thioredoxin like domain is depicted as a red colored box. Substrate binding domain b is
illustrated as a blue box. Transmembrane domain is labeled with TMD in a purple box
(Hatahet et al, 2009; Kozlov et al, 2010).
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Figure 1.2. Disulfide exchange reactions carried out by PDIs. Red: Reduces substrate.
A) Reduction of disulfide bond from a disulfide bond to two sulfhydryl groups. B)
Oxidation of the substrate from the reduced form to more oxidized disulfide bond. C. and
D) Exchange of disulfide linkages without changing the overall oxidative nature of the
substrate. C. Isomerization involves changing the overall folding of the substrate, D.
disulfide bond altercation with limited changes on the protein conformation (Essex,
2009).
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A.

B.

Figure 1.3. Mechanism of substrate oxidation and isomerization by PDIs. A) Oxidation of
the client protein (C) by passage of disulfide bond from PDI. PDI exert a nucleophile
attack on one of the substrate’ cysteine residue, followed by the formation of mixed
disulfide bond with the substrate. Then the second sulfur atom of the PDI initiates a
second attack on the mixed disulfide sulfur of PDI releasing the substrate active thiol ion
from the PDI. The active thiol of the substrate then attacks the second Cys of on the
same protein to form a disulfide bond. B) PDIs break the existing disulfide bonds within a
protein substrate to allow for the formation of new bonds between two new Cys residues
(Hatahet et al, 2009).
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Figure 1.4. Possible sources of disulfide bonds in PDIs. A) Vitamin K epoxide reductase
(VKOR) thioredoxin domain gets oxidized during reduction process of vitamin K epoxide
to vitamin K; the disulfide bond is passed to PDIs. B) Glutathione peroxidase 7 and 8
(GPx7, 8) used oxidoreductin (Ero1) -produced H2O2 to oxidized PDIs. C) Ero1 used
molecular oxygen to generate disulfide bond and releasing H2O2 then passes the
disulfide bond to PDIs. D) Reduction of dehydroascorbate to ascorbate by PDIs. E)
PrxIV consumes H2O2 to generate interchain disulfide bond (depicted as one unit),
before passing it to PDIs. F) Quiescin-sulfhydryl oxidase (QSOX) couples generation of
disulfide bonds to molecular oxygen reduction reaction to produce H2O2, and then the
disulfide is passed directly to the substrates. Disulfide bond generated via coupling
TXNDC5 or PDIA6 with Ero1 and PrxIV have been experimentally validated (depicted in
the dashed box), the other pathways are hypothetical suggestions based on that
documented for PDIA1 protein (Bulleid & Ellgaard, 2011; Lu & Holmgern, 2014; Bulleid,
2012; Shepherd et al, 2014).
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PDI is shown to couple ER stress with oxidative stress through three ROSgenerating pathways activated during UPR. Those pathways are ER flavor oxidase
Ero1, Nox4 in Nox family NADPH oxidase isoform, and physical linkage with
mitochondria. While H2O2 can promote protein folding, increased ER load of
un/misfolded protein triggers UPR. Furthermore, UPR activation is generally
accompanied by increases in ROS and ER stress (Laurindo et al, 2012). The
un/misfolded proteins sequestered by 78 kDa glucose-regulated protein (GRP78), 94
kDa glucose-regulated protein (GPR94) and Calreticulin regulators. These modulators
trigger UPR sensors in the cytosolic side of ER membrane. There are UPR tributaries to
three response pathways: PRKR-like ER kinase (PERK)–eukaryotic translation initiation
factor 2α (eIF2α), inositol-requiring protein 1α (IRE1α)–X-box binding protein 1 (XBP-1),
and activating transcription factor 6α (ATF6α) (Wang et al, 2014). The initial results of
UPR activation are adaptation and correction of this ER stress through halting of overall
protein synthesis, increasing expression of chaperone proteins to correct the misfolded
proteins, and direction of the misfolded proteins to the ERAD (ER associated
degradation) degradation pathway. Furthermore, UPR activation can arrest the cell cycle
at the G1 phase through the PERK pathway. PERK activation causes decrease in the
expression of cyclin D1 via the phosphorylation of translation elongation initiation factor
eIF2α (Brewer & Diehl, 2000). However, if the cells are incapable of recovering ER
homeostasis, death-signaling pathways are triggered. Extended IRE activation can
initiate apoptotic ASK/JNK and Bcl2 pathways. CCAAT/enhancer-binding protein
homologous protein (CHOP) transcription factors are activated via PERK/activating
transcription factor 4 (ATF4) or ATF6 pathways resulting in apoptosis (Laurindo et al,
2012). It is important to note that the ROS generated UPR in some cells do not show
increases in oxidative stress due to antioxidant system upregulation (Laurindo et al,
2012; Watson, 2013). PDIs, particularly PDIA1, are recognized to be key enzymes in
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oxidative protein folding in the ER to prevent protein misfolding and aggregation.
Moreover, the redox regulation of PDIA1 chaperone activity has been shown to play a
protective role in preventing activation of the UPR pro-apoptotic pathway (Wang et al,
2014; Xu et al, 2013). It is well established that tumor cells activate UPR during
oncogenic transformation as survival strategy in stressful microenvironments and that
UPR activation is associated to cancer growth and chemoresistance (Wang & Kaufman,
2014). ATF6α activation upregulates the expression of GRP78. GRP78 overexpression
has been associated with the malignancy of colon, skin, kidney, and ovary cancer.
Increased XBP-1 splicing has been associated with chemoresistance and short survival
in lymphoma B cells (Wang & Kaufman, 2014). Furthermore, the deletion of PERK
interrupts mammary tumor development and reduces metastasis of lung cancer cells
(Bobrovnikova-Marjon et al, 2010).
Even though the roles of PDI family members in cancer development have not
been established, many studies have indicated PDIs overexpression in different types of
cancer. PDIA1 is associated with clinical outcomes and tumor survival and progression.
PDIA1 is overexpressed in lymphoma, brain, kidney, lung, prostate, and ovary cancers.
PDIA1 inhibition by bacitracin was found to sensitize aplidin-resistant Hela cells to
aplidin (Xu et al, 2014). PDIA3 is upregulated in cancers of prostate (Pressinotti et al,
2009), laryngeal (Choe et al, 2015), breast (Ramos et al, 2015), colon (Caorsi et al,
2015; Ren et al, 2006). Similar to PDIA1, PDIA3 protected Hela cells from aplidininduced cytotoxicity (Laurindo et al, 2012). PDIA4 has been found to be upregulated in
leukemia (Voss et al, 2001), and liver cancer (Chen et al, 2008; Laurindo et al, 2012).
However, the association between the levels of the majority of PDI members and cancer
progression requires further investigation. The following paragraphs focus on expression
of the Srx-interacting PDIs TXNDC5 and PDIA6 in cancer.
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TXNDC5 and PDIA6 in cancer
The TXNDC5 gene is located at Chr6p24.3 and encodes a 432 amino acid
protein. It has N-terminal signal peptide of 32 amino acids, and C-terminal KDEL ER
retention signal and three CGHC domains. TXNDC5 was discovered in 2003 in two
parallel studies by Sullivan and Knoblach to protect normal and tumor endothelial cells
from

undergoing

apoptosis.

Under

hypoxic

conditions,

TXNDC5

becomes

overexpressed and modulates anti-apoptotic proteins. However, the biochemical
mechanisms of TXNDC5 have not been studied, particularly its role in disulfide bond
exchange, chaperon activity, and UPR activation in lung cancer. TXNDC5 expression is
upregulated in lung (Vincent et al, 2011), prostate (Wang et al, 2014), colon (Wang et al,
2007), gastric (Wu et al, 2015), breast, cervical, esophageal, liver (Nissom et al, 2006),
and ovarian cancers (Chang et al, 2013). Because of its role in enhancing cancer cells
proliferation, colony formation and cell migration; TXNDC5 is believed to act as an
oncogene (Chang et al, 2013; Wu et al, 2015).
Cell fractionation and microscopic studies show that most of TXNDC5 proteins
are located in the ER and Golgi organelles. Thus, they are believed to be involved in
protein folding and anterograde transport. Meanwhile, nearly one fifth of the total
TXNDC5 proteins are present on the surface of the plasma membrane, and they are
presumably involved in events on the cell surface (Charlton et al, 2010). For instance,
knockdown of TXNDC5 affects the presence of AdipoR1 (Adiponectin Receptor 1)
presence on surface of plasma membrane through affecting its trafficking and
endocytosis process (Charlton et al, 2010). TXNDC5 interacts directly with Androgen
receptor (AR), which is enhanced by dihydroxytestosterone. TXNDC5 binds and
stabilizes AR structure, and consequently AR transcription activity and responsiveness
to different ligands changes. An example of these ligands is estrogen, which enhances
signaling of AR to promote growth of prostate cancer cells. As a result, TXNDC5 acts as
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an alternative pathway for AR activation when androgen hormone is limited in castrationresistant prostate cancer (CRPC) (Wang et al, 2014). TXNDC5-AR interaction protects
AR from degradation and assists its translocation to the nucleus, which indicates that
TXNDC5 acts as a chaperone for AR.
TXNDC5 is upregulated in androgen naïve prostate cancer and in CRPC. There
was more protein expression in androgen-independent cancer than in androgendependent cancer. Also, TXNDC5 promotes LNCaP adenocarcinoma cell proliferation in
the presence of androgen. It has been shown that downregulation of TXNDC5 in
androgen-independent LNCaP-AI, PC3, and VCap cells decreases their invasiveness. In
vivo studies have shown larger tumors when TXNDC5-derived LNCaP cells are injected
into xenograft models of male Balb/c athymic nude mice (Wang et al, 2014). TXNDC5
overexpression in prostate cancer, which occurs in response to low levels of androgen
hormone, sensitizes the cells to activated protein kinase B (AKT), extracellular-signalregulated kinases (ERKs)1/2, and human epidermal growth factor receptor 2 (HER2)
(Wang et al, 2014). TXNDC5 knockdown in Hela cells increased phosphorylation of
AMP-activated protein kinase (AMPK). However, the phosphorylation of P38 mitogenactivated protein kinases (p38MAPK) was reduced (Duivenvoorden et al, 2014,
Charlton, 2010). In renal cell carcinoma (RCC), AdipoR1 has the opposite effect, where
the reduced AdipoR1 and adiponectin levels are associated with increased
aggressiveness in RCC. Overexpression of TXNDC5 aggravates metastasis of clear-cell
RCC in vitro and increases RCC tumor growth after subcutaneous injection into nude
mouse models (Duivenvoorden et al, 2014).
TXNDC5 expression is elevated in pre-cancerous lesions in gastric cancer. In
gastric adenocarcinoma, MKN45, and normal gastric epithelial cell line, HFE145,
demonstrated that TXNDC5 could affect cell characteristics in normal and cancer cells.
TXNDC5 overexpression enhances tumor formation by affecting the proliferation rate of
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the cell. Zhang et al reported that TXNDC5 upregulation increases number of cells in the
G2/M phase of cell cycle, while TXNDC5 downregulation increases number of cells in
G0/G1 phase (2010). They also reported more cell migration and colony formation and a
lower rate of apoptosis in gastric cells with overexpressed TXNDC5 (Zhang et al, 2010).
This anti-apoptotic action is further supported in pancreatic cancer, where the prooncogene NR4A1 orphan nuclear receptor and TXNDC5 are overexpressed. NR4A1
downregulation leads to ER defragmentation and concurrent alteration of expression of
many of ER stress proteins, such as ATF-4, GRP78, TXNDC5, and CHOP (Lee et al,
2014). NR4A1 is involved in sustaining endoplasmic reticulum stress and directly
regulates TXNDC5 transcription in pancreatic and renal cancers. Thus, NR4A1
enhances the overexpression of TXNDC5 protein to reduce ER stress, consequently
leading to decreases in pro-apoptotic CHOP activities (Lee et al, 2014; Hedrick et al,
2015).
TNFα (tumor necrosis factor-alpha) -treated human umbilical vein endothelial (HUVE)
cells showed less phosphorylation of ERK1/2 when TXNDC5 was knockdown by siRNA,
and this decrease was attributable to inactivation of Ras and Raf. However, the
phosphorylation of p38 MAP and JNK kinase was found to be unaffected by TXNDC5
downregulation. NF-κB (nuclear factor of kappa light polypeptide gene enhancer in bcells 1) signaling represented by IκBα degradation and ICAM expression. ERK
inactivation has been found to reduce activity of AP-1, which results in decreased
expression of angiogenesis inducing proteases, matrix MMP9 and cathepsin B. For this
reason, TXNDC5 is believed to enhance angiogenesis of endothelial cells (Camargo et
al, 2013). Moreover, studies on rheumatoid arthritis (RA) show that TXNDC5 may lead to
an increase in MMP1 and MMP13 proteases. MMP1 enzyme is overexpressed in
cancers and is suggested to be involved in cancer cell invasion and metastasis (Sauter
et al, 2008). MMP13 has been associated with promoting tumor angiogenesis through
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focal adhesion kinase and ERK signaling and secretion of vascular endothelial growth
factor A from endothelial and fibroblast cells (Kudo et al, 2012). It is likely that TXNDC5
modulates the activity metalloprotease to enhance metastasis, invasion, and
angiogenesis of cancer cells.
TXNDC5 protein is highly expressed in endothelial cells of tumor tissues and
atherosclerotic plaques, particularly under hypoxic conditions. Knockdown of TXNDC5
reduces endothelin-1, adrenomedullin, and CD105 levels. These protein molecules are
known to protect endothelial cells from hypoxia. It has been proposed that TXNDC5 has
a protective role against hypoxia-induced cell death in endothelial cells (Sullivan et al,
2003). In prostate cancer, androgen-deprivation treatment (ADT) leads to increases in
TXNDC5 protein expression under hypoxic conditions through the HIF-1α and miR-200b
signaling pathway. In addition to TXNDC5, expression of AR also increases. Moreover,
the hypoxic condition fortifies the interaction between TXNDC5 and AR and their
downstream signaling pathways (Wang et al, 2014). The hypoxic conditions caused by
CoCl2 in TXNDC5-overexpressing PC cells also sensitize the cells to ERK1/2, AKT
pathways. Hypoxia induces TXNDC5 expression in RA. Hypoxia’s effect on TXNDC5
expression can be explained by activity of miR-200b, which targets 3’ UTR TXNDC5
mRNA (5′-CAGUAUU-3′), which reduces TXNDC5 expression. HIF-1α and miR-200b
are involved in prostate cancer progression, and it is possible that HIF-1α indirectly
regulates TXNDC5 expression under hypoxic conditions through miR-200b pathway,
where HIF-1α stabilization leads to miR-200b downregulation (Wang et al, 2014). miR200b downregulation is associated with increased angiogenesis and cell migration
(Chan et al, 2011).
The PDIA6 gene is located at Chr2p25.1 and encodes a protein of 440 amino
acids. It has an N-terminal signal sequence of 19 amino acids and C-terminal KDEL
sequence. PDIA6 contains two CGHC domains and one b domain. It has been reported
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that PDIA6 has both chaperone and isomerase activity. Isomerase activity has been
credited mainly to the N-terminal cysteine residues at both active CGHC sites. The
promoter region of PDIA6 contains ERSE elements to which spliced ER XBP-1 binds
after activation of UPR. Thus, PDIA6 expression can be induced during ER stress (Eletto
et al, 2014; Groenendyk et al, 2014). Furthermore, PDIA6 can bind to ER stress marker,
GRP78, suggesting a possible role of PDIA6 in assisting GRP78 in protein folding.
PDIA6 has been verified to assist in platelet aggregation and activation through
modulating receptors on the surface of plasma membranes (Galligan & Petersen, 2012).
However, few studies available regarding the role of PDIA6 protein in the
development of lung cancer. Nonetheless, PDIA6 has been found to be upregulated in
head and neck squamous cell carcinoma. It has also been found to protect Hela cells
from aplidin-induced cytotoxicity (Laurindo et al, 2012). PDIA6 exerts a chemopreventive
effect in cisplatin-resistant non-small-cell lung cancer cells (Tufo et al, 2014). It was
found to translocate to the nuclei of treated tumor cells but not in normal cells. PDIA6
knockdown prompted increases in caspase 4 activation causing receptor-interacting
serine/threonine-protein kinase 1 (RIPK1) upregulation, thus activating programmed
necrotic death pathways (Tufo et al, 2014). PDIA6 overexpression is associated with
neoplastic transformation in invasive ductal carcinomas of breast cancer. More PDIA6
was observed in metastatic lymph nodes than in controls (Ramos et al, 2015).
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Research objectives
Srx connects several main redox-regulating systems in cells. Therefore,
additional elucidation of its function could make it a creditable target for lung cancer
treatment. In this study we aimed to find additional function of Srx in cancer through its
interacting proteins. Moreover, we attempted to understand the consequences of Srxprotein interaction on the physiology of the cells and in lung cancer development. We
hypothesis that Srx-interacting protein are essential for enhancing oncogenic
characteristics of Srx in lung cancer cells. TXNDC5 and PDIA6 oncogenic phenotype
recapitulate that of Srx enzyme.
Specific aims:
A. In chapter two, I aimed to substantiate Srx interaction with each of TXNDC5 and
PDIA6 in cells and determine the protein domains responsible for these
interactions. Moreover, through subcellular fractionation Srx was determined to
localize in the ER. The co-localization of Srx with TXNDC5 and PDIA6 were
characterized by immunofluorescence and immunprecipitation methods.
B. Experiments of chapter three were aimed at clarifying physiological functions of
Srx, TXNDC5, and PDIA6 in lung cancer cells, particularly in the ER
compartment. Role of each protein in chaperone activity, in response to different
ER stressor, is examined, in addition to their role in UPR sensors activation.
Luciferase refolding assay, XTT assay, RT-PCR, and Western blot methods were
employed to elucidate these functions.

The roles of TXNDC5 and PDIA6 in

oncogenic phenotypes in lung cancer cells were characterized. Cell proliferation,
anchorage independent colony formation, and cell migration were examined. In
addition, role of TXNDC5 and PDIA6 in phosphokinase signaling in response to
epidermal growth factor was demonstrated.
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1.2. Materials and methods
Cell lines and chemicals
Human embryonic kidney cells (HEK293T) and human lung adenocarcinoma cell lines
(A549, H226 and H2030) were purchased from ATCC. Dulbecco's Modified Eagle
Medium (DMEM) (Thermo scientific; Lonza Bio Whittater) supplemented with 10% fetal
bovine serum (FBS) (Atlanta Biologicals) was used to culture HEK293T cells. Roswell
Park Memorial Institute-1640 (RPMI-1640) medium (Hyclone) supplemented with 10%
FBS was used to culture the cancer cell lines. Penicillin- streptomycin solution (Hyclone,
Thermo scientific) [penicillin is 100 U/ml and streptomycin 100 µg/ml] and 5 µg/ml
gentamycin (gibco, Life Technologies) were added to the media before use. Puromycin
(gibco, Life Technologies), 1 µg/ml, was added to maintain the lentiviral generated stable
cell lines. The cells were incubated in humidified atmosphere with 5% (v/v) CO2 at 37˚C.
Hydrogen peroxide and tunicamycin were purchased from Sigma-Aldrich.
Plasmid constructs and lentiviral production
A. pcDNA 3.1/ TXNDC5- Myc-His, pcDNA 3.1/ PDIA6- Myc-His constructs, and
pcDNA 3.1/ Srx- Myc-His construct:
1. Total RNA was extracted from HEK293T cells following RNeasy Mini Kit
(Qiagen).
2. First Strand cDNA of TXNDC5 and PDIA6 were synthesized by ProtoScript
II Reverse Transcriptase kit (New England Biolab).
3. The PCR was set to Initial denaturation temperature of 94°C for 5min,
denaturation 94°C 30sec, annealing 68 ° C, extension 68°C and final
extension 72°C for 10min, in a total of 30 cycles.
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4. The products were digested with either Xho I and Xba I restriction enzymes
for TXNDC5, HindIII and Xbal restriction enzymes for PDIA6, or BamHI and
EcoRI restriction enzymes for Srx.
5. Empty pcDNA 3.1/ - Myc-His constructs were digested with the
corresponding restriction enzymes for each of the cDNAs.
6. After DNA ligation, the constructs were amplified by Top 10 bacteria
(Invitrogen), followed by Maxi prep (Qiagen)
7. The correct sequence for each of TXNC5, PDIA6, and Srx were verified by
sequencing (Appendix).
B. Constructs for stable overexpressed cells:
1. To tag cDNA of TXNDC5 and PDIA6 with Flag sequence, the cDNA of these
genes were subcloned from pcDNA3.1 myc-His A vector to p3xFLAG-CMV14 vector.
2. For TXNDC5-Flag NotI and XbaI restriction sites were used while for PDIA6
HindIII and Xbal enzymes were used.
3. Then the cDNA of the genes tagged with Flag were sub-cloned from
p3XFLAG-CMVTM-14 vector to PLVX - IRES-PURO expression vectors.
4. Primers with restriction BstB1 and Sall enzymes were generated for both
TXNDC5 and PDIA6. Forward primer with Sall restriction site was: 5’
CATCGTCGACGTTGCTAAGCTTGCG 3’. The reverse primer with BstB1
restriction site was: 5’ CGGTTCGAAGGATCACTACTTGTCG 3’.
5. After DNA ligation, the constructs were amplified by Top 10 bacteria
(Invitrogen), followed by Maxi prep (Qiagen)
6. The correct sequence for each of TXNC5 and PDIA6, were verified by
sequencing.
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C. Constructs for stable knockdown cells:
1. Short hairpin constructs were purchased from Sigma-Aldrich to knockdown
TXNDC5 and PDIA6 expressions.
2. All ShRNA constructs including MISSION pLKO.1-puro control vector
(vector control), MISSION Non-Target shRNA (ShNT) and ShRNAs
specifically targeting either TXNDC5 (ShTXNDC5), or PDIA6 (ShPDIA6)
were commercially obtained (Sigma-Aldrich).
D. Generation of lentiviral particles
1. The Lentiviral particles were generated following instructions provided in
MISSION Lentiviral Packaging Mix manual (Sigma-Aldrich).
2. Lentiviral particles were produced in HEK293T cells using the provider’s
plasmid packaging system and PolyJet transfection reagent (3:1). And the
viral soup stored in -80C.
3. To establish stable cell lines, A549 and H2030 cells were cultured in
35mm dish till 90% cell confluence.
4. The cells were infected with 1ml of the viral soup.
5. The remaining steps was followed as instructed by the manual
6. Cells were maintained in puromycin containing medium to establish
stable cells.
7. A549 Flag Srx, HEK293T Flag Srx, and H226 knockdown cells were
provided by Dr. Qiou Wei lab, University of Kentucky.
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Site directed mutagenesis
A. Mutation of Srx cysteine 99 residue (C99A)
1. Site directed mutagenesis was used to mutate cysteine99 residue (TGC) to
alanine (GCC).
2. Protocol provided by QuikChange II site directed mutagenesis kit (Agilent
Technologies) was followed as instructed.
3. Forward 5’ TACTCCTTTGGGGGCGCCCACCGCTACGCGGCC 3’ and
reverse 5’ GGCCGCGTAGCGGTGGGCGCCCCCAAAGGAGTA 3’primers
were used.
4. The generated constructs were amplified by Top 10 bacteria (Invitrogen),
followed by Maxi prep (Qiagen)
5. The correct sequence for each of TXNC5 and PDIA6, were verified by
sequencing (Integrated DNA Technologies).
B. Thioredoxin like fold deletion in TXNDC5:
1. Site directed mutagenesis was also used for thioredoxin like domain
deletion, pcDNA 3.1/ TXNDC5- Myc-His plasmid. One deletion per
construct was prepared.
2. Protocol provided by QuikChange II site directed mutagenesis kit (Agilent
Technologies) was followed as instructed.
3. The primers used are listed bellow:
The primers for N-terminus thioredoxin like domain (D1) deletion
(Del1):
Forward primer: 5’ATCCAGAGCGCCGCGCACAATGACCTGGGAGAC 3’
Reverse primer:
5’ GTCTCCCAGGTCATTGTGCGCGGCGCTCTGGAT 3’.
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The primers for second thioredoxin like domain (D2) deletion (Del2):
Forward primer:
5’ GTTGCACAAGGCGACCACGAGCAGCTGGCTCTGGGCCTTG 3’
Reverse primer:
5’ CAAGGCCCAGAGCCAGCTGCTCGTGGTCGCCTTGTGCAAC 3’
The primers for the C-terminus thioredoxin like domain (D3) deletion
(Del3):
Forward primer
5’CGATGACACCATTGCAGAAGGAATAACCGAGGAACTCTCTAAAAAGG
3’
Reverse primer
5’CCTTTTTAGAGAGTTCCTCGGTTATTCCTTCTGCAATGGTGTCATC3’
4. Presence of the desired deletion was verified by sequencing (Integrated
DNA Technologies).

C. Thioredoxin like fold deletion in PDIA6:
1. Site directed mutagenesis was also used for thioredoxin like domain
deletion, pcDNA 3.1/ PDIA6- Myc-His plasmid. One deletion per construct
was prepared.
2. Protocol provided by QuikChange II site directed mutagenesis kit (Agilent
Technologies) was followed as instructed.
3. The primers used are listed bellow:
The primers for N-terminus thioredoxin like domain (D1) deletion (Del1):
Forward primer:
5’GTTATTCAGAGTGATAGTTTGTGGAAGAAAGCAGCAACTGC 3’
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Reverse primer:
5’ GCAGTTGCTGCTTTCTTCCACAAACTATCACTCTGAATAAC 3’
The primers for the C-terminus thioredoxin like domain (D2) deletion
(Del2):
Forward primer:
5’GGACAGTGAAGATGTTTGGGCTGCCGCAGCTTCAG 3’
Reverse primer:
5’TAGGCTCTAGAGTCAGCCACAACACAGAGCTGGTGCTCCTC3’
The primers for Truncation of C-terminal amino acids in PDIA6 are:
Forward primer:
5’ GTTAAGCTTATGGCTCTCCTGGTGCTCGGTCTGGTG3’
Reverse primer:
5’ TAGGCTCTAGAGTCAGCCACAACACAGAGCTGGTGCTCCTC3’
4. Presence of desired deletion was verified by DNA sequencing (Integrated
DNA Technologies).
Protein purification
Prokaryotic system was used to purify Srx and TXNDC5 recombinant proteins.
1. Srx and TXNDC5 cDNA were subcloned from pcDNA 3.1/ Myc-His plasmids to
pRSET B constructs.
2. BL21 bacteria were used to amplify translation of the genes.
3. 1M IPTG was used to induce translation of the proteins in the bacterial culture.
The cells were pelleted and lysed.
4. Then Ni-Affinity Chromatography was used to purify the proteins. Ni was
employed to bind Histidine tagged TXNDC5 or Srx proteins.
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5. The proteins eluded by 250mM imidazole buffer.
6. The imidazole was exchanged with 1X PBS by dialysis using Pur-A-Lyzer Midi
Dialysis Kit (Sigma) Samples stored in -20°C before the co-immunprecipitation
experiments.
Immunoprecipitation and immunohistochemistry
A. Immunoprecipitation
1. The cells lysed using either NP-40 lysis buffer (rpi CORP) or
immunoprecipitation buffer (50mM HEPES pH7.5, 150mM NaCl, 1mM
EDTA, 10% Glycerol, 0.1 % Tween-20, and 0.5% Triton X100) mixed with
protease inhibitors.
2. A volume of 250-400µl of lysis buffer was added to each 100mm cell
culture plate. The plates were incubated at 4°C for 1-2hr.
3. The lysate centrifuged at 15000rpm for 10min at 4°C.
4. A volume of 100µl supernatant was used as input control. The rest of the
lysate was mixed with 20µl of magnetic beads for co-immunoprecipitation
part.
5. Dynabeads Protein A (life technologies), Protein G magnetic beads (New
England BioLab) or ANTI-FLAG M2 Magnetic Beads (Sigma-Aldrich,)
were used.
6. The samples incubated overnight at 4°C. After using magnetic separator
to collect the beads, the lysate was discarded at the end of the incubation
period.
7. The beads washed in cold immunoprecipitation buffer (without Triton
x100) and re-suspended in 1X Laemmli sample buffer with βmercaptoethanol before boiling at 90°C for 10min.
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8. Magnetic separated was used to separate the denatured samples from
the beads before loading on SDS-PAGE gel for Western blot.
9.

When antibody-free magnetic beads were used, 10µl of the primary
antibody was incubated with the supernatant overnight, and then the
beads were added. The samples incubated for additional 2hr at 4°C
before proceeding to Western blot.

10. For

purified

recombinant

Srx

and

TXNDC5

proteins

co-

immunoprecipitation experiment, 2µg of Srx protein was mixed with 10µg
of TXNDC5 protein in 500µl immunoprecipitation buffer. The mixture was
incubated for 2hr at 4°C. Then 10µl of anti-Srx antibody was added to the
mix and incubated at 4°C overnight. A Dynabeads Protein magnetic bead,
20 µl per sample, was mixed with the samples before incubation for 2hr at
4°C. Then beads were washed and processed for Western blot.
11. The samples loaded on commercial SDS-PAGE gels, 4-12% gel
(Invitrogen), and transferred using nitrocellulose or PVDF membranes
B. UPR experiment
1. The cells were seeded in 35 mm dishes and treated for either 4,6,8,12, and 24hr
with 2μg/ml of Tunicamycin diluted in RPMI medium, 10% FBS.
2.

The cells were scarped to a microcentrifuge tube and pelleted at 1500rpm for
5min.

3. The pellet were suspended in 100μl NP-40 buffer and lysed for 5min at 4C. The
lysate centrifuged at 15000rpm for 10min at 4C.
4.

The supernatant was saved as a cytosolic fraction.

5. The pellets re-suspended in another 100μl NP-40 and sonicated for 30 sec and
used as a nuclear fraction.
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6. Both fractions were mixed with Laemmli sample buffer and β-mercaptoethanol
before being boiled at 95C.
7. The samples were loaded on 12% SDS-PAGE gel and transferred to PVDF
membranes. The membranes were blotted for GRP78, XBP-1 (Santa Cruz
Biotechnology), phosphorylated eIF2α (Cell Signaling), and β-Actin (Sigma)
antibodies. The band detected in nuclear fraction near 50 kDa was considered as
Spliced XBP-1 protein.
C. Phosphokinase signaling experiment
1. A549 cells cultured in 35 mm dish, serum free RPMI medium with antibiotics was
used to starve the cells for 16hr.
2. Epidermal growth factor (EGF), 100ng/ml, prepared in 10% FBS RPMI medium
was added to the cells for different durations: 0, 7,15,30,60 or 120min.
3. The cells lysed using 200µl RIPA buffer with protease inhibitors.
4. The lysate centrifuged at 15000 at 4C for 10min.
5. The supernatant was mixed with Laemmli buffer and β-mercaptoethanol, and
boiled for 10min at 90C.
6. The samples loaded on 4-12% SDS-PAGE commercial gel (Invitrogen) for
Western blot.
D. Immunohistochemistry staining
Normal human and lung cancer tissue microarray slides were purchased
from Biomax.US. Slide of multiple organ normal tissue array, 47 cases/99 cores
(Cat# FDA 999 J256) and lung disease spectrum tissue microarray with 99 cases
/100 cores (Cat# BC04002 057) were used. The lung cancer slide contained five
cases of carcinoid, five cases of inflammatory pseudotumor, and ten cases of
metastatic carcinoma, ten of each of small cell undifferentiated carcinoma and
alveolar cell carcinoma, twenty cases of each squamous cell carcinoma and
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adenocarcinoma, in addition to tuberculosis, adjacent tissue, adjacent normal
tissue and normal tissue.
1. The slides rehydrated in xylene and ethanol 100, 95, 70% respectively.
2. The slides immersed in antigen retrieval solution made of 10% target retrieval
solution (10x)

(Dako, Ref S1699), 90% glycerol, and 1mM EDTA (Fisher

Scientific).
3. Primary anti TXNDC5 antibody (Santa Cruz biotechnology, Cat# sc-271465)
prepared in mouse in a dilution of 1:50 (Antibody Diluent, DakoCytomation, Ref #
S0809) and it is added to the slides for 2hr.
4.

Then biotin-streptavidin counjugated horseradish peroxidase (HRP) secondary
antibody added Chromatogen DAB (3, 3 -diaminobenzidine) was used as a HRP
substrate that produced a dark brown reaction product as instructed by Dako
LSAB2 System-HRP kit (Ref K0673).

5. The slides stained for 1 min with Hematoxylin, followed by dehydration in 70, 95,
100% and clearing with xylene.
6.

Images and quantification of the slide staining in each core is analyzed by
measuring the intensity of the brown stain by using Image Scope software,
version 11.2.0, (Aperio Technologies).

7. Percent of positive pixel is plotted against the tissue organs of each slide. The
data is presented as Mean±SEM.
E. Antibodies used
7. Anti-TXNDC5 antibody (Santa Cruz biotechnology, Cat# sc-271465) was diluted
1:1000 in 5% BSA. PDIA6 (Santa Cruz biotechnology, Cat# sc-271465), PrxIV
(Abcam, ab59542), PrxIII (Santa Cruz biotechnology, Cat#, sc-33574), β-actin
(Sigma, A2228), flag (Sigma, F3165) antibodies were incubated in 5% dry milk
prepared

in

TBS.

Antibodies

for
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phosphorylated

c-Jun,

Total

c-Jun,

phosphorylated ERK1/2, Total ERK1/2, total AKT and phosphorylated AKT (Cell
Signaling), in 1:1000 dilutions in 5% Bovine serum albumin (BSA) were used.
Secondary anti-mouse and anti-rabbit antibodies (R&D systems; cell signaling)
used in concentrations of 1:5000 for 1hr at room temperature. SuperSignal West
Dura Chemiluminescent Substrate (Thermoscientific) was used to enhance HRP
signals from the secondary antibodies.

Prediction of tertiary structures and docking sites
1. Protein sequenced for Srx, TXNDC5, or PDIA6 protein (Appendix) was entered
to

I-TASSER

server

for

protein

structure

and

function

prediction

(http://zhanglab.ccmb.med.umich.edu/I-TASSER/).
2. The predicted structure with the highest score was used in the experiments.
3. Molecular visualization of the results was prepared by Pymol software (DeLano
Scientific LLC).
4. Srx and TXNDC5, or Srx and PDIA6 structures in step 2 were inserted into
ZDOC server, to predict Srx docking sites with either TXNDC5 or PDIA6
(http://zdock.umassmed.edu).
5. The model with the highest score was used in the experiments to hypothesize for
Srx-TXNDC5/PDIA6 complex formation.

Methods references: (Roy et al., 2010; Yang et al., 2015; Pierce et al., 2014)
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Subcellular fractionation
1. A549 cells were cultured in 100mm dishes until 90% confluence. Three dishes
prepared per group.
2. The cells lysed in chilled homogenization buffer (0.25M sucrose, 25mM KCL,
10mM HPES). Protease inhibitor cocktail was added to the lyses buffer before
use.
3. The lysate were moved to 2ml microcentrifuge tubes filled to 1/4th with 1.0 mm
glass beads (BioSpec).
4. MiniBeadBeater-16 (BioSpec, Model 607) was used to homogenize the cells for
3min.
5.

A fraction of cell lysate was saved as a total cell fraction and stored at -20°C.

6. The rest of the sample centrifuged at 15000rpm at 4°C for 15min to remove
mitochondrial, nuclear, and cytoskeletal fractions.
7. After centrifugation a part of the supernatant was saved as cytosolic fraction. The
cytosolic fraction was centrifuged for additional 30min, at 20 000 rpm to remove
microsomal fractions.
8. The rest of ER containing supernatant was centrifuged at 35 000 rpm for 70min at
4°C using Beckman SW41 Ti rotor.
9. The supernatant was discarded and the microsomal fractions washed with 1X
PBS by centrifugation at 35 000 rpm for 10min.
10. Then the sediments were lysed using 1X Laemmli sample buffer with βmercaptoethanol prepared in ddH20.
11. Equal amount of total and cytosolic fractions lysed using Laemmli sample buffer
with β-mercaptoethanol and loaded on 4-12% gel for Western blot.
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12. Anti-Calnexin (Santa Cruz) was used as an ER marker. Anti-GAPDH (Santa Cruz)
was used as a cytosolic marker and Anti-PrxIII (Santa Cruz) antibody was used
as a mitochondrial marker.
Immunofluorescence imaging
1. 3000 cells per chamber were cultured in either DMEM or RPMI medium

for

HEK293T and A549 cells respectively.
2. The media were supplemented with 10% FBS for 24hr.
3. After 24hr, the cells were fixed with chilled methanol for 10min. followed by
wash step with 1X PBS, pH 7.5.
4. The cells were incubated in 5% goad serum blocking buffer (goat serum diluted
in 1% BSA prepared in 1X PBS), for 45-60min at room temperature. Followed
by a 5min wash step with TBST (0.01% Tween 20).
5. The primary and secondary antibodies prepared in dilution of 1:100, and 1:1000
respectively, prepared in 1% BSA diluted in 1X PBS. The 150µl of the primary
antibodies added to each chamber and incubated for 2hr at room temperature.
6. The excess primary antibody was removed by TBST wash.
7. The fluorescently labeled secondary antibody was added for 1hr, in a dark
humid container.
8.

Same steps starting from blocking buffer were repeated to blot for the second
primary antibody.

9. The slides slightly air-dried. A drop of DAPI containing prolog-anti fade was
added to the slide and covered with cover slip.
10. The slides stored a dark container in 4°C until analysis by confocal microscope.
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Intracellular refolding assay
1. A549, H2030, or H226 cells were cultured in 12 well plate (n=4) till 85%
confluence.
2. PolyJet reagent was used to transfect the cells with 1µg pGL3 luciferase reporter
vector for 24hr.
3. To control for luciferase translation during refolding process, Cyclohexamide
(10µg/ml) was added to the growth medium 30min prior to treatment.
4. The cells either treated with either non-lethal doses of heat-shock, 42°C for
30min in water bath, or 1mm H2O2 at 37°C for 10min.
5. The medium in the well changed to fresh RPMI medium (10% FBS) and the cells
returned back to 37°C incubator.
6. The cells were scraped in 1ml RPMI growth medium at different time points and
centrifuged at 15000 for 1min.
7. The pellets lysed by adding 100µl passive lyses buffer (Promega) per sample.
8. The samples were mixed with luciferase substrate and read by Luminometer of
GloMax-Multi Detection System (Promega).
9.

The readings are represented as Mean±SEM of the samples.

A detailed

procedure of intracellular refolding assay can be found in Walther et al
publication (2012).
Clonogenic cell survival assay
Moderate hyperthermia has been demonstrated to sensitize cells to radiation and
chemotherapy-induced responses, in vitro as well as in vivo. This hyperthermia-induced
response inhibits tumor growth (Urano, 1986; Carper, 1987). To test if TXNDC5 or
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PDIA6 affects lung cancer cells tolerance to heat treatment, clonogenic cell survival
assay was employed. The procedure used is as follows:
1. A549 cells were cultured in RPMI medium in 35mm dish till 90% confluence.
2. Then the cells subjected to heat at 42°C in a water bath for different durations:
30min, 60min, or 120min.
3.

After treatment, equal number of cells were cultured in 35mm dish, under
standard growth condition of 37°C for 8 days.

4. The cells were fixed with 100% methanol and stained with 0.1% crystal violet.
5. After removing excess stain by 1x PBS, image of the plates were taken.
6.

Then the colonies were scraped and re-suspended in water.

7. Absorbance of the stain was measured at 560nm. The readings of the treated
groups were compared to that of the control group.
8. The data are presented as Mean±SEM of the samples (n=3).
Reverse transcription polymerase chain reaction (RT-PCR)
1. A549 or H226 (4X105) cells were seeded in 35 mm dishes for 24hr.
2. Tunicamycin (1-2 µg/ml) was used to treat the cells for different durations in their
growth medium.
3. Total RNA extracted by RNeasy Mini Kit (Qiagen). First Strand cDNA Synthesis
Kit using Protoscript II Reverse Transcriptase kit (New England Biolab) was used
to amplify the cDNA of interest.
4.

PCR reaction contained primers for either XBP-1 or GAPDH in a total reaction
mixture of 50μl:
Forward XBP1: 5’ TTACGAGAGAAAACTCATGGCC 3’
Reverse XBP1: 5’ GGGTCCAAGTTGTCCAGAATGC 3’
Forward GAPDH: ‘CAACGAATTTGGCTACAGCA 3’
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Reverse GAPDH: 5’ AGGGGTCTACATGGCAACTG 3’
5. The PCR setting included 30 sec of 94C of initial denaturation, 94C for 45sec
denaturation, 52C for 45sec annealing, and 72C for 30 sec of extension in a total
of 34 cycles, and 72C for 8min of final extension.
6.

MetaPhor Agarose (Lonza) was used to prepare electrophoresis gel in
concentration of 3%. 1X TBE buffer (54g Tris-Base, 27.5g Boric acid, 20ml of
0.5M EDTA in 1L water to make 5X buffer) was prepared to run the gel.

7. 10-12 μl of PCR products mixed with cyber green (10X) and run on the agarose
gel at 80V for 4-5 hr.
8. Image of the amplified gene of interest was captured.
9. The percent of spliced XBP-1 (sXBP-1) band intensity was compared to the total
XBP-1 band intensities (sXBP-1+ unspliced XBP-1 (uXBP-1) at each time point,
GAPDH was used as a control for the procedure.
XTT Assay
1. In 96 well plates, 2X103 cell were seeded per well in 100µl RPMI, phenol red free
mediums.
2.

XTT reagents (Roche Cell Proliferation Kit II [XTT], or Trevigen’s TACS XTT cell
proliferation assay kit) were added starting from the day of seeding, referenced
as day 0, up to 5 days.

3.

After adding XTT reagents, cells incubated for 3-4hr at 37°C. Reading of the
cell media were measured at 490nm and 600nm by GloMax-Multi Detection
System (Pormega), and the values subtracted.

4.

For cell proliferation assay the values are plotted as fold increase in growth in
each day compared to day 0 (Mean±SEM).
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5. In cell viability assay, the cells treated with different concentrations of
tunicamycin (μg/ml) for 4 days. Then the cell viability was measured. Microsoft
excel was used to calculate IC50.
Anchorage independent colony formation assay
1. Six well plates (35mm dishes) were used to layer a 1.5ml of agar (0.5%) (Sigma).
The agar prepared in RPMI medium, supplemented with 10% FBS and left to
solidify.
2.

A top agar layer (0.35%) prepared in RPMI was mixed with 7X103 – 10X104 cell
/well. 1.5ml of this mixture added to each well and left to solidify.

3.

The colonies nourished with 1.5 ml of RPMI medium, 10% FBS.

4.

To avoid fungal contamination 25ng/ml of amphotericin A (Fisher Scientific) was
added to medium.

5.

The plate incubated for 30 days at 37˚C, with occasional change of the medium.

6. The wells fixated for 10min with absolute methanol, and stained for 20min with
0.25% Crystal Violet. Excess stain was removed with 1XPBS.
7.

The colonies were examined under 4X to calculate colonies larger than50 µm
used for statistical analysis.

Wound healing assay
1. A549 cells (5x105) were cultured in 35 mm dishes (n=4) and supplied with RPMI
medium containing 10% FBS.
2. The following day a scratch (wound) was made in the cells monolayer by using
200-microlitter tips, perpendicular to the surface of the cells.
3.

The floated cells were washed twice with 1XPBS.

4. RPMI, supplied with 10%FBS, added to the cells. The cells incubated at 37˚C.
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5. Image of the cells were taken each 24hr, starting from day 0 up to day 3.
6. The remaining wound gap was measured in each day and compared to image of
the same scratch of day 0.
7. The data represented as Mean±SEM of remaining gap.
Subcutaneous or tail-vein injection Of A549 cells into SCID mice
1. Severe combined immunodeficiency (SCID) female mice, 6-week of age, were
injected in tail vein with nearly 5 × 105 cells/mouse (in 100 μl of PBS).
2. After 8 weeks the animals were sacrificed.
3. Lung tissues were collected and fixed with 4% paraformaldehyde and saved in
70% ethanol.
4. The tissues proceeded with standard paraffin embedding, sectioning, H&E
staining and histopathological examination.
5. Anti-TXNDC5 antibody (Santa Cruz) was used to immunoblotted for TXNDC5
proteins.
6. The intensity of the TXNDC5 staining in the tumor site is compared to the normal
surrounded lung tissue.
Statistical analysis
Data were analyzed by two-tailed student t-test. Numbers presented as mean ±
SD (or SEM). 95% was used as confidence interval. The difference was defined to be
statistically significant at p-values ≤ 0.05.

Copyright © Hedy Chawsheen 2016
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CHAPTER TWO
VERIFICATION OF THE SRX-TXNDC5/PDIA6 INTERACTION
2.1. Results
2.1.1 Co-immunprecipitation of Flag tagged Srx with TXNDC5 and PDIA6
TXNDC5 and PDIA6 proteins were co-immunoprecipitated with Flag-Srx in
HEK293T cells (Wei et al, 2011). The identities of the PDI proteins were confirmed by
mass spectrometry in HEK293T and A549 cells (Figure 2.1).

A.

B.

Figure 2.1. Co-immunprecipitation of Flag tagged Srx with TXNDC5 and PDIA6. A)
Silver staining showing pull-down of approximately 48 kDa band of TXNDC5 and PDIA6
with Srx tagged with Flag in HEK293T cells, In addition to immunprecipitation of 2-Cys
Prxs (I, II and IV). B) Mass Spectrometry was used to verify identity of TXNDC5 and
PDIA6 proteins (Wei et al., 2011).
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2.1.2 Srx interacts directly with TXNDC5 in vitro

In order to verify Srx-TXNDC5 interaction, purified recombinant Srx and TXNDC5
proteins were co-immunoprecipitated. The Western blot result confirms pull down of
TXNDC5 with Srx indicating their direct interaction in vitro (Figure 2.2).

14 kDa
48 kDa

Figure 2.2. Srx interacts directly with TXNDC5. Co-immunprecipitation of purified
recombinant Srx and TXNDC5 proteins. Srx and TXNDC5 form a protein complex in
vitro.
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2.1.3 The active site cysteine residue of Srx is dispensable in the SrxTXNDC5/PDIA6 interaction
Since cys99 is considered the key of catalytic center in Srx, It was expected SrxTXNDC5/PDIA6 interaction to be cys99 residue dependent (Figure 2.3A). To test this
prediction HEK293T cells were transfected with either wild type or mutant Srx constructs
(C99A), tagged with Flag. Co-immunoprecipitation results do not display significant
differences in the detected TXNDC5 or PDIA6 protein levels pulled down with Srx. Thus,
cys99 of Srx is unessential for Srx-TXNDC5/PDIA6 interaction (Figure 2.3B).

A.

B.
48 kDa
50 kDa
30 kDa
14 kDa

Figure 2.3. The interaction of Srx with TXNDC5/ PDIA6 is independent of Srx catalytic
function. A) The architecture of human Srx. The only catalytically active cysteine residue
(C99) was mutated to alanine by site directed mutagenesis. B) Co-immunprecipitation of
Srx tagged with Flag with TXNDC5 and PDIA6 in HEK293T cells transfected with either
wild type Flag-Srx (WT) or cysteine 99 mutant Srx (C99A) constructs. PrxIV is used as a
control.
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2.1.4 The interaction of Srx with TXNDC5/PDIA6 is thioredoxin-like
domain dependent

To identify protein domain in TXNDC5 responsible for its interaction with Srx, ITASSER prediction software was used to obtain the tertiary structure of both proteins
(Figure2.4. A and B). The model with the highest score in Z-doc software was selected
to predict the domain of Srx-TXNDC5 interaction. Based on this prediction, it was
hypothesized that TXNDC5 N-terminal (D1), and C-terminal (D3) thioredoxin like
domains to be responsible for its interaction with Srx (Figure 2.4.D). To test this
assumption HEK293T flag tagged Srx cells were transfected with c-Myc tagged
TXNDC5 constructs, with deleted thioredoxin like domains (Figure 2.5. A). The lysates
were immunoprecipitated for Flag, then the Western blot membrane immunoblotted for
TXNDC5 using c-Myc antibodies. The results indicate the N-terminal thioredoxin like fold
(D1) to be required for the Srx-TXNDC5 interaction, whereas the third thioredoxin like
fold (D3) to be only partially involved in this interaction (Figure 2.6).
I-TASSER prediction software was used to obtain the tertiary structure of PDIA6
(Figure2.4. C). In Z-doc predicted model with the highest score, PDIA6 was expected to
interact with Srx via PDIA6 C-terminal domain (Figure 2.4.E). However, our
immunprecipitation result showed no effect of this domain on Srx-PDIA6 interaction
(data not shown). Therefore, similar to TXNDC5, It was hypothesized thioredoxin like
fold to be responsible for this interaction. To test this hypothesis, HEK293T flag tagged
Srx cells were transfected with constructs of PDIA6 tagged with c-Myc, with a deleted
thioredoxin like domain (Figure 2.5 B). The cell lysates were immunoprecipitated for
Flag, and then the Western blot membranes were immunoblotted for PDIA6 using c-Myc
antibodies. The result shows the N-terminal thioredoxin like fold (D1) to be required for

42

the Srx-PDIA6 interaction, whereas the second thioredoxin like fold (D2) to be only
partially involved in this interaction (Figure 2.7).
A.

B.

C.

E.

D.

Figure 2.4. Prediction of domains responsible for the Srx-TXNDC5/PDIA6 interaction. A,
B, and C) Predicted full-length Srx, TXNDC5 and PDIA6 proteins, respectively, using ITASSER server for protein structure and function prediction, Blue: N-terminal first
methionine amino acid residue, red: CGHC motif (labeled as D), and yellow: C-terminal
KDEL. D) Z-doc prediction result of Srx (Blue) interaction with TXNDC5 (Green) through
D1 and D3 of TXNDC5. E) D) Z-doc prediction result of Srx (Blue) interaction with PDIA6
(Green) C-terminal domain.

43

A.

B.

Figure 2.5 Constructs generated for examining the Srx-TXNDC5/PDIA6 interactions by
site directed mutagenesis. A) The architecture of human TXNDC5. Each thioredoxin like
domain consists of 18 amino acids, domain 1 (D1) starts from 81 to 99, domain 2 (D2)
starts from 209 to 227, and domain 3 (D3) starts from 342 to 360 amino acids. B) The
architecture of human PDIA6. Each thioredoxin like domain consists of 18 amino acids,
domain 1 (D1) starts from 45 to 63, domain 2 (D2) starts from 389 to 407.Thioredoxin
like motif consists of cysteine-glycine-histidine-cysteine (CGHC) sequence located within
thioredoxin like domains. Both TXNDC5 and PDIA6 have N-terminal signal peptide (SP)
and C-terminal Lys-Asp-Glu-Leu (KDEL) ER sequence retention signal.
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48 kDa
14 kDa

Figure 2.6. Srx interacts with thioredoxin like fold of TXNDC5. Immunprecipitation of
TXNDC5 with Srx is mainly dependent on N-terminal thioredoxin-like domain (D1) of
TXNDC5 in HEK293T-Flag-Srx cells. Only one thioredoxin like domain deleted in the
transfected c-Myc-tagged TXNDC5 construct. Del1 indicates deletion of D1, amino acids
from 81- 99. Del2 indicates deletion of D2, amino acids from 209- 227. Del3 indicates
deletion of D3, amino acids from 342- 360 by site directed mutagenesis.

50 kDa
14 kDa

Figure 2.7. Srx interacts with thioredoxin like fold of PDIA6. Immunprecipitation of
PDIA6 with Srx is mainly dependent on N-terminal thioredoxin-like domain (D1) of PDIA6
in HEK293T-Flag-Srx cells. One thioredoxin like domain deleted in transfected c-Myctagged PDIA6 construct. Del1 indicates deletion of D1, amino acids from 45- 63. Del2
indicates deletion of D2, amino acids from 389- 407 by site directed mutagenesis.
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2.1.5. Srx co-localizes with TXNDC5/PDIA6 in the ER
Both TXNDC5 and PDIA6 are known to be ER resident proteins. Therefore, I
sought to find if Srx could enter the ER. I treated A549 with increasing concentration of
H2O2 for 10min. The Western blot result verified presence of Srx in the ER fraction, even
in the absence of H2O2. And that TXNDC5 increases in the ER in correlation with
increased doses of H2O2 (Figure 2.8). However, there are no obvious changes in PDIA6
and PrxIV levels.
The immunofluorescent staining of Srx with ER maker Calnexin verified colocalization of Srx with Calnexin in lung adenocarcinoma cells (Figure 2.9. A). I further
verified co-localization of Srx with each of TXNDC5 and PDIA6 in HEK293T and A549
cells (Figure 2.9. B, and C, respectively). HEK293T has low endogenous Srx expression
therefore I used HEK293T overexpressed Srx tagged with Flag and used anti-Flag
primary antibody to blot for Srx. Srx is labeled with red fluorescent color in all panels of
Figure 2.9, whereas Calnexin, TXNDC5, and PDIA6 labeled with green fluorescent color
secondary antibodies. The overlap of the two colors produced a yellow staining
indicating their co-localization (Figure 2.9).
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14 kDa
48 kDa
50 kDa
30 kDa

Figure 2.8. Srx co-localizes with TXNDC5 and PDIA6 in the ER. Western blot for A549Flag-Srx cells treated for 10min with increasing concentration of H202 (mM). Srx can be
detected in the ER fraction along with TXNDC5 and PDIA6. ER resident PrxIV is blotted
as a control.
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A.

B.

C.
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Figure 2.9. Srx co-localizes with TXNDC5 and PDIA6 in the ER. A) Immunofluorescent
staining for Srx (red) and ER marker Calnexin (green) showing their localization (yellow)
in A549 cell. B) Immunofluorescence staining for Srx (red) and TXNDC5 (green)
showing

their

localization

(yellow)

in

HEK293T

and

A549

cell

lines.

C)

Immunofluorescence staining for Srx (red) and PDIA6 (green) showing their localization
(yellow) in HEK293T and A549 cell lines.
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2.1.6. Srx-TXNDC5 interaction is enhanced under acute oxidative stress
conditions
As Srx interaction with TXNDC5 and PDIA6 is redox sensitive thioredoxin like
domain dependent, Srx-PDIs interaction was hypothesized to enhance under oxidative
stress conditions. Immunprecipitation of A549 overexpressed TXNDC5 cells, tagged with
Flag, was employed. The cells were treated with increasing concentration of H2O2 for 10
min and immunoblotted with Srx antibodies. The results show discernible correlation
between increased Srx affinities to TXNDC5 with increased concentration of H2O2.
These results suggest that Srx-TXNDC5 interaction is boosted under oxidative stress
conditions (Figure 2.10).
To investigate role of acute exposure of H2O2 on Srx affinity to PDIA6 in lung
cancer cells, A549 overexpressed Srx cells, tagged with Flag, were treated with H2O2.
The co-immunprecipitation experiments show a slight increase in PDIA6 binding to Srx
at the highest treated dose of H2O2 of 1mM, whereas, no change in PrxIV affinity to Srx
was observed in response to acute H2O2 exposure (Figure 2.11).
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A.

48 kDa
46 kDa

B.

14 kDa
48 kDa

Figure 2.10. Increased binding of Srx to TXNDC5 under oxidative stress conditions. A)
Verification of TXNDC5 knockdown (ShTXNDC5) and overexpression (Flag-TX) in A549
cells. B) Co-immunprecipitation of Flag tagged TXNDC5 with Srx in A549 cells after
treatment with H202 (mM) for 10min. The result shows a gradual increase in Srx binding
to TXNDC5 in response to increase in H2O2 concentration.
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14 kDa
50 kDa
30 kDa

Figure 2.11. Co-immunoprecipitation of Srx with PDIA6 in A549 cells. Srx coimmunprecipitation with PDIA6 in A549 cells after treatment with H2O2 (mM) for 10min.
The result shows slight increase in Srx binding to PDIA6 only the highest concentration
of in H2O2 treatment, whereas no change in PrxIV affinity to Srx is observed.
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2.2 Discussion

Srx provides a critical defense mechanism against oxidative stress through
reactivation of overoxidized 2-Cys Prx in cells. Reactivation of catalytic activities of 2Cys Prx, hence, facilitates H2O2 scavenging during oxidative stress (Pace et al., 2013).
Among four members of 2-Cys Prxs (Prx I-IV), Srx preferentially binds with PrxIV. In fact,
Srx-PrxIV axis is considered critical for enhancing oncogenic characteristics in lung
cancer. Depletion of PrxIV recapitulates the oncogenic phenotypes similar to that
observed in Srx knockdown cells (Wei et al., 2011). In this dissertation, I sought to
examine additional functions of Srx in lung cancer, through studying Srx interacting
proteins.
Besides PrxIV, ER resident proteins, TXNDC5 and PDIA6 Ire identified to interact
with Srx. Both proteins belong to PDI family of enzymes. PDIs are a group of more than
twenty enzymes; which structurally share one or more thioredoxin-like domains. This
redox sensitive domain contains CXXC fold, which is implicated in oxidoreductase
activity of PDIs. The specific function of the majority of PDIs is not identified. However,
many members are known to take part in oxidation (formation), reduction (breakdown),
and isomerization (rearrangement) of disulfide bonds in nascent proteins to facilitate
their maturation to physiologically functional proteins in the ER (Bulleid, 2012). PDIs
become oxidized before interacting with their reduced protein substrates. There are
several well-established pathways involved in the oxidation of PDI CXXC fold in
mammalian cells. Ero1 and 2-cys Prxs are among these pathways (Bulleid, 2012; Bulleid
et al., 2011; Lu et al., 2014). TXNDC5 holds three CGHC thioredoxin-like fold. The Cterminal thioredoxin-like domain has extended long loop, offering TXNDC5 extended Vshape configuration compared to the U-shaped feature of other PDI family members,
such as protein PDIA1, PDIA3, and PDIA4. Additionally, the TXNDC5 CGHC folds
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function independently from one another, providing the enzyme the capacity for rapid
involvement in oxidoreductase activities. In contrast to TXNDC5, the two CGHC domains
of PDIA1 function cooperatively and in a slower rate during substrate oxidative folding.
The dimeric PrxIV is reported to form a mixed disulfide bond with the second
thioredoxin-like domain of TXNDC5 during oxidative folding (Kojima et al., 2014). In this
study, a novel interaction between TXNDC5 and Srx is identified.

The N-terminal

thioredoxin-like fold of TXNDC5 is determined to be primary interaction site while the Cterminal fold is only partially involved. This Srx-TXNDC5 interaction, which is Srx Cys99
independent, is enhanced by oxidative stress. Previous cell fractionations experiments
reported that the majority of TXNDC5 proteins are present in the ER and Golgi
compartments. Therefore, it was proposed TXNDC5 to function in protein folding in the
ER and retrograde transport of substrates from Golgi to ER (Charlton et al., 2010). This
may explain the TXNDC5 concentrations increase in the ER fraction in correlation to
increased H2O2 concentration. Even though our results detected Srx in the ER, no
changes in Srx levels were observed with increased H2O2 concentration in A549 cells.
TXNDC5 is reported to interact with specificity with hyperoxidized forms of PrxII and
PrxIV (Pace et al., 2013). It is well established that Prx hyperoxidation stabilizes the Prxs
decameric structures. In contrary, reduced forms of Prxs causes disruption of decamer
interactions, including PrxII-TXNDC5 interaction (Pace et al., 2013); therefore, it is likely
that Srx interacts with TXNDC5 to prevent TXNDC5 from stabilizing the decameric
structures of PrxIV during acute oxidative stress. Hence, leaving more PrxIV available in
the ER to participate in H2O2 scavenging.

This interpretation can be supported by

enhanced Srx-TXNDC5 interaction in correlation to increased H2O2 concentration
observed in the results.
PDIA6 has two thioredoxin-like folds and one b domain. Thus, in addition to
CGHC related oxidoreductase activity, PDIA6 is expected to have isomerase activities
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as well.

The results demonstrate that PDIA6 interacts with Srx through PDIA6 N-

terminal

thioredoxin-like

domain.

This

interaction

insinuates

redox-sensitive

oxidoreductase activity between PDIA6 with Srx. However, the results do not display
change in the level of Srx-PDIA6 interaction with increased H2O2 concentration.
Therefore, I propose Srx to have a higher affinity toward TXNDC5 compared to its
affinity to PDIA6 under acute oxidative stress conditions.
In summary, in this chapter, a novel interaction between antioxidant protein Srx
with each of TXNDC5 and PDIA6 were corroborated. PDIs are the main players in ER
quality control system that permits for only correctly folded secretory proteins to enter
the secretory pathway. PDIs play an important role in the processes of disulfide bond
oxidation, reduction, and isomerization in the client proteins. Consequently, the
substrates will be retained in the ER until they are correctly folded. Otherwise, PDI
proteins will direct the terminally misfolded substrates to the ER degradation pathway.
Furthermore, PDIs can pass electrons to members of antioxidant systems in the ER,
such as Ero1 and 2-CysPrx pathways; the resulted disulfide bonds in PDIs are used to
oxidize substrates in the process of oxidative protein folding. Therefore, Srx interaction
with the redox sensitive thioredoxin like folds in TXNDC5 and PDIA6 suggests a novel
function of Srx in modulating members of the ER quality control system in response to
oxidative stress in lung cancer.
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CHAPTER THREE
PHYSIOLOGICAL FUNCTION OF SRX, TXNDC5, AND PDIA6 IN LUNG CANCER
3.1. Results
3.1.1. TXNDC5 facilitates the retention of Srx in the ER
Even though there are no reports regarding its biochemical functions in lung
cancer, TXNDC5 is involved in androgen receptor (AR) stabilization in prostate cancer to
facilitate AR translocation to the nucleus. Therefore, TXNDC5 or PDIA6 were proposed
to interact with Srx to stabilize Srx presence in the ER. The Western blot results for A549
subcellular fractionation supported this prediction for TXNDC5. As the ER level of Srx is
significantly reduced in TXNDC5 knockdown cells compared to the control cells. The
results also demonstrate less PrxIV in the cytosolic fraction of ShTXNDC5 cells.
Therefore it is suggested that TXNDC5 is required for Srx retention in the ER in lung
adenocarcinoma cells. However, PDIA6 deficient cells did not show any obvious change
in the level of Srx and PrxIV compared to the control cells (Figure 3.2).

Figure 3.1. Verification of knockdown and overexpression of PDIA6 in A549 cells.
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A.

B.

C.

D.

E.
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Figure 3.2. TXNDC5 facilitates Srx retention in the ER of A549 cells. A) Western blot for
A549 TXNDC5, and PDIA6 knowdown cells showing decrease in Srx presence in the ER
in ShTXNDC5 but not in that ShPDIA6 cells after normalization with ER marker
Calnexin. B) and C) Quatitative analysis of relative band intensitity for Srx protein in
TXNDC5, and PDIA6 knowdown cells, respectvily. D) and E) Quatitative analysis of
relative band intensitity for PrxIV protein in TXNDC5, and PDIA6 knowdown cells,
respectvily. GAPDH is used as a cytosolic marker. PrxIII is used as mitochondrial
marker.
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3.1.2. TXNDC5 and Srx protects against heat-shock induced protein aggregates

Cell exposure to nontoxic doses of stressors such as metals, ethanol, low heatshock temperatures (40-45°C) and oxidants acquire cells the capacity to develop a
temporary endurance (thermotolerance) to otherwise lethal doses of that stressor after
succeeding exposure. These stressors cause protein aggregation and misfolding.
Molecular chaperones are proteins with various cellular functions including disassembly
of protein aggregates, protein refolding, and substrate transport (Freeman et al, 2000;
Hoffmann et al, 2010; Hartl et al, 2011). Several members of PDI family, such as PDIA1
and PDIA3, are known to have chaperone activities (Vinaik et al., 2013).
To investigate the chaperone activities of Srx, TXNDC5, and PDIA6 intracellularrefolding assay was employed.

The cells were transfected with luciferase coding

construct for 24hr. The cells treated with heat at 42°C for 30min to generate protein
aggregates. Then the cells capacity to recover the aggregates represented by luciferase
activity over times was measured. The results show decrease in luciferase activity in
ShTXNDC5 A549 cells compared to the control cells; meanwhile Flag-TXNDC5 cells
appear to protect luciferase from losing its activity (Figure 3.4 A). Decrease in luciferase
activity was also observed in H2030 shTXNDC5 cells (Figure 3.4 B). Heat shock
treatment of A549 cells did not demonstrate significant differences in aggregate recovery
in PDIA6 and Srx downregulated and overexpressed cells. (Figures 3.5 and 3.6 A,
respectively). However, significant decrease in luciferase activity was observed in H226
Srx knockdown cells compared to the control cells under same treatment conditions
(Figure 3.6 B).
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Figure 3.3 Western blot showing no increase in translation of luciferase proteins after
heat-shock (HS) treatment. A549 cells are treated with Cyclohexamide 30min in
advance of heat-shock treatment to inhibit translation of luciferase gene.
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A.

B.

Figure 3.4. TXNDC5 participates in the recovery of heat-shock induced protein
aggregates. A) intracellular refolding assay in A549 cells. B) intracellular refolding assay
in H2030 cells. Both cell lines were treated with heat at 42°C for 30min. Recovery of
luciferase activity was followed over a period of 4hr after treatment. The data were
analyzed by student t-test.

Numbers presented as mean ± SEM, using 95% as

confidence interval. The difference was defined to be statistically significant at p-values ≤
0.05.
61

Figure 3.5. PDIA6 does not affect recovery of heat-shock induced protein aggregates.
A549 cells were treated with heat at 42°C for 30min. Recovery of luciferase activity was
followed over a period of 2hr after treatment. Data were analyzed by using student t-test.
Numbers presented as mean ± SEM, using 95% as confidence interval. The difference
was defined to be statistically significant at p-values ≤ 0.05.
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A.

B.

Figure 3.6. Srx participates in the recovery of heat-shock induced protein aggregates in
H226 cells. A) intracellular refolding assay in A549 cells. B) intracellular refolding assay
in H226 cells. H226 cells demonstrates a protective role of Srx in preveting aggretate
after heat shock treatment at 42°C for 30min. Data were analyzed by using student ttest. Numbers presented as mean ± SD (or SEM), using 95% as confidence interval.
The difference was defined to be statistically significant at p-values ≤ 0.05.
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3.1.3. TXNDC5 and PDIA6 enhance cellular capacity for oxidative protein
folding
Wang et al (2011) demonstrated that the chaperone activity of PDIA1 is redox
regulated. And that oxidation of PDIA1 activates its chaperone activity through PDIA1
conformation change. Moreover, Sato et al (2013) revealed that oxidized TXNDC5 to
interact with PrxIV decameric structure that participates in oxidative substrate folding.
This interaction was verified to abolish under reduced conditions. Therefore, it was
anticipated that TXNDC5 and PDIA6 to show similar activities to PDIA1 in lung cancer
cell lines. The cells were subjected acutely to H2O2 for 10min. The luciferase activity was
followed at different time points. The results indicate significant decrease in the recovery
of luciferase activity in ShTXNDC5 cells in both A549 as well as H2030 adenocarcinoma
cell lines compared to the control cells (Figure 3.7 A and B, respectively). Luciferase
activity was also reduced in PDIA6 deficient cells subjected to H2O2 treatment compared
to the control A549 cells (Figure 3.8). The results demonstrate TXNDC5 and PDIA6
promote the process of protein folding under oxidative stress conditions.
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A.

B.

Figure 3.7. TXNDC5 promotes protein folding under acute oxidative stress conditions. A.
A549 cells. B) H2030 cells. In both H2O2 (mM) treated cell lines, luciferase activity is
reduced in TXNDC5 downregulated cells compared to the control cells. While TXNDC5
overexpression enhaces luciferase activity in A549 cells. Data were analyzed by student
t-test.

The data represented as Mean ± SD, using 95% confidence interval. The

difference was defined to be statistically significant at p-values ≤0.05.
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Figure 3.8. PDIA6 enhances protein folding under acute oxidative stress conditions in
A549 cells. H2O2 (mM) induced luciferase actiivty is decreased in PDIA6 knockdown
cells compared to control cells. PDIA6 overepxression enhaces luciferase activity. Data
were analyzed by student t-test. The data are presented as Mean ± SD, using 95%
confidence interval. The difference was defined to be statistically significant at p-values
≤0.05.
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3.1.4. Srx suppresses oxidative protein folding
ShSrx A549 and ShSrx H226 cell lines showed significant increase in luciferase
activity after acute exposure to H2O2, for 10min(Figure 3.9 A and B). Srx overexpression
reduced luciferase activity in A549 cells. Hence, the results indicate Srx to oppose
folding process under oxidative stress conditions. The results also display PrxIV to
enhance oxidative protein folding in lung cancer (Figure 3.9 C); supporting previously
published chaperone function of PrxIV under oxidative stress conditions.

A.

.
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B.

C.

Figure 3.9. Srx suppresses protein folding under acute oxidative stress conditions. H2O2
(mM) induced luciferas activity is promoted in Srx knockdown A549 cells (A), and in Srx
knockdown H226 (B) cells. While PrxIV overepxression enhaces luciferase folding (C).
Data were analyzed by student t-test. The data presented as Mean ± SD, using 95% as
confidence interval. The difference was defined to be statistically significant at p-values ≤
0.05.
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3.1.5. TXNDC5/PDIA6 are dispensable in heat- shock induced thermotolerance
Our result shows no observable change in lung cancer cell ability to survive
different duration of heat shock treatment when TXNDC5 protein expression was
downregulated or overexpressed in A549 cells (Figure 3.10). Therefore, TXNDC5 does
not protect lung cancer cells against hyperthermia induced tumor growth inhibition. Our
result shows no observable change in lung cancer cell ability to survive different duration
of heat-shock treatment when PDIA6 protein expression was manipulated in A549 cells
(Figure 3.11). Thus, similar to TXNDC5, PDIA6 does not provide thermotolerance
against hyperthermia induced tumor growth inhibition.

A.
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B.

Figure 3.10. TXNDC5 does not provide thermotolerance in clonogenic cell survival
assay. TXNDC5 does not affect the ability of cells to form colonies in response to
different durations of heat shock treatment. A) Crystal Violet stained TXNDC5
downregulated and overexpressed cells. B) Quantification of fold change in the intensity
of Crystal Violet stain measured at 560nm, showing no significant differences compared
to control cells.
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A.

B.

Figure 3.11. PDIA6 does not provide thermotolerance in clonogenic cell survival assay.
PDIA6 does not affect the ability of cells to form colonies in response to different
durations of heat shock treatment. A) Crystal Violet stained PDIA6 downregulated and
overexpressed cells. B) Quantification of fold change in the intensity of Crystal Violet
stain measured at 560nm, showing no significant differences compared to control cells.
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3.1.6. The Srx-interacting proteins protect against tunicamycin induced growth
inhibition in lung cancer
Tunicamycin induces ER stress through Inhibition of protein glycosylation. An
overall accumulation of under-glycosylated proteins in the ER of malignant tumors has
been reported to inhibit cell growth and promote apoptosis. For instance, tunicamycin
induces apoptosis in melanoma cells via depletion of functional insulin-like growth factor
1 receptor at the cell surface (Dricu et al, 1997). The results of cell viability assay
demonstrate TXNDC5 to have protective effect on sensitizing A549 (Figure 3.12 A) and
H2030 (Figure 3.12 C) to tunicamycin induced growth inhibition. Lung cancer PDIA6
deficient cells showed similar response to tunicamycin treatment in both A549 as well as
H2030 cells (Figure 3.13 A and C, respectively). Half maximal inhibitory concentration
(IC50) of tunicamycin was reduced from 1.49 μg/ml to 0.51 μg/ml in A549 cells (Table 3),
and from 1.49 μg/ml to 0.93 μg/ml in H2030 cells (Table 5). The results also indicate
more prominent tunicamycin induced cell proliferation inhibition in ShSrx A549 cells
compared to the control cells measured by XTT (Figure 3.15). IC50 was reduced from
1.49 μg/ml to 0.2 μg/ml (Table 5).
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A.

A549 Viability
Mean IC50 (µg/ml)

n

ShNT

1.49

6

ShTXNDC5

0.88

6
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C.

D.
H2030 Viability
Mean IC50 (µg/ml)

n

ShNT

1.44

6

ShTXNDC5

1.07

6

Figure 3.12.TXNDC5 protects against tunicamycin induced growth inhibition. TXNDC5
depletion sensitizes cancer cells to tunicamycin in A549 (A) and H2030 (C) cells. Mean
values of replicates are shown. B and D) Calculated mean of IC50 of tunicamycin in
ShNT and ShTXNDC5 cells for A and C, respectively.
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A.

B.

A549 Viability
Mean IC50 (µg/ml)

n

ShNT

1.49

6

ShPDIA6

0.51

6
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C.

D.

H2030 Viablity
Mean IC50 (µg/ml)

n

ShNT

1.49

6

ShPDIA6

0.93

6

Figure 3.13. PDIA6 protects against tunicamycin induced growth inhibition. PDIA6
depletion sensitized cancer cells to tunicamycin in A549 (A) and H2030 (C) cells. Mean
values of replicates are shown. B & D) Calculated mean of IC50 of tunicamycin in ShNT
and ShPDIA6 cells for A and C, respectively.
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A.

B.
A549 Viability
Mean IC50 (µg/ml)

n

ShNT

1.49

6

ShSrx

0.2

6

Figure 3.14. Srx protects against tunicamycin induced growth inhibition in A549 cells. A)
Srx depletion sensitizes cancer cells to tunicamycin. Mean values of replicates are
shown. B) IC50 of tunicamycin in ShNT and ShSrx cells.
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3.1.7. TXNDC5 downregulation accelerates XBP-1 splicing
Reverse transcription PCR (RT-PCR) was applied to study role of Srx, TXNDC5,
and PDIA6 in UPR induction lung cancer cells. ShTXNDC5 cells were treated with
tunicamycin (1µg/ml) for 0,1,2,4, and 6 hr. Whereas ShPDIA6, and ShSrx cells were
treated for 30min, 1, 2, and 4 hr. After extraction of mRNA, PCR was made for reverse
transcribed XBP-1 (spliced and un-spliced). Our results indicate that TXNDC5
knockdown cells are more prone to have XBP-1 spliced (sXBP-1) than the control. As it
is shown in figure 3.15, majority of the XBP-1 is in spliced after 1hr of chemical
treatment, while in the control group was spliced after 2hr tunicamycin treatment.
ShPDIA6 and ShSrx cells subjected to tunicamycin treatment did not display observable
differences in the ratio of spliced to total XBP-1 compared to the control cells.
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A.

B.

C.

Figure 3.15. TXNDC5 depletion accelerates XBP-1 splicing in response to tunicamycin
treatment in A549 cells. A) RT-PCR result of XBP-1 cDNA run on 3% agarose gel. B)
Quantification of percent of spliced to total XBP-1 in A. sXBP-1: spliced XBP-1, uXBP-1:
unspliced XBP-1, bands are compared at each time point. C) Representation of percent
relative XBP-1 band intensity at each time point.
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A.

B.

C.

Figure 3.16. PDIA6 depletion does not affect splicing of XBP-1 in response to
tunicamycin treatment in A549 cells. A) RT-PCR result of XBP-1 cDNA run on 3%
agarose gel. B) Quantification of percent of spliced to total XBP-1 in A. sXBP-1: spliced
XBP-1, uXBP-1: unspliced XBP-1, bands are compared at each time point. C)
Representation of percent relative XBP-1 band intensity at each time point.
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A.

B.

C.

Figure 3.17. Srx depletion does not affect splicing of XBP-1 in response to tunicamycin
treatment in H226 cells. A) RT-PCR result of XBP-1 cDNA run on 3% agarose gel. B)
Quantification of percent of spliced to total XBP-1 in A. sXBP-1: spliced XBP-1, uXBP-1:
unspliced XBP-1, bands are compared at each time point. C) Representation of percent
relative XBP-1 band intensity at each time point.
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3.1.8. TXNDC5 depletion accelerates XBP-1 splicing
Western blot experiment for ShTXNDC5 H2030 cells, treated for 0, 4, 6,8,12, or
24hr with 2μ/ml tunicamycin, showed faster XBP-1 splicing compared to the control cells.
More sXBP-1 protein was detected 4hr after tunicamycin treatment in comparison to the
control cells (Figure 3.18). The overall expression of sXBP-1 and GRP78 are decreased
in ShTXNDC5 cells compared to the control cells. Thus, the results suggests protective
role of TXNDC5 against premature splicing of XBP-1, besides regulating of ER
chaperone GRP78 expression. Western blot experiment showed decrease in UPR
sensor activation, sXBP-1, in response to 2μ/ml tunicamycin, when ShSrx H226 cells
treated for different durations, 4, 6, 8, 12,24hr (Figure 3.19). Besides, less GPR78 was
expressed 12hr after the treatment compared to the control cells. Therefore, it is
concluded here that Srx to play a vital role in XBP-1 and GRP78 signaling during
tunicamycin induced UPR.

A.
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B.

C.

Figure 3.18. TXNDC5 depletion accelerates XBP-1 splicing. A) Western blot for H2030
ShTXNDC5 cells treated for different durations (hr) with tunicamycin (2μg/ml) showing
spliced XBP-1, and GRP78 protein expression change. C: control with no treatment. B
and C) Quantification of intensity of Western blot band of sXBP-1, and GRP78 proteins
in A, respectively.
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A.

B.

C.

Figure 3.19. Srx depletion decreases XBP-1 and GRP78 signaling. A) Western blot for
H226 ShSrx cells treated for different durations (hr) with tunicamycin (2μg/ml) showing
spliced XBP-1, and GRP78 protein expression change. C: control with no treatment. B
and C) Quantification of intensity of Western blot band of sXBP-1, and GRP78 proteins
in A, respectively.
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3.1.9. TXNDC5 is upregulated in lung cancer
To screen for TXNDC5 protein expression in normal tissues, human tissue
microarray slides were immunoblotted for TXNDC5. In contrary to Srx protein that is only
expressed under oxidative stress conditions, TXNDC5 expression varies in different
tissues (Figure 3.20). The immunohistochemistry results of lung tissues shows TXNDC5
protein expression to be significantly lower in normal tissues than cancer tissues in
adenocarcinoma, bronchioloalveolar carcinoma, squamous cell carcinoma and small
cells carcinoma represented by the intensity of brown staining (Figure 3.21).

A.

B.

85

Figure 3.20. Variation in TXNDC5 protein expression in normal tissues A) TXNDC5
protein expression in panel of normal tissue B) Quantitative analysis of positive staining
in A.

A.

B.

Figure 3.21. TXNDC5 is upregulated in lung cancer. A) Immunohistochemistry for
TXNDC5 protein expression in different lung cancer tissues. B) Quantitative analysis of
positive staining in A. The data presented as Mean ± SD, using 95% as confidence
interval. Lung cancer tissue compared to the control and the difference was defined to
be statistically significant at p-values ≤ 0.05.
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3.1.10. TXNDC5 promotes tumorigenesis in lung cancer

To investigate effect of TXNDC5 in sustaining proliferative rate of A549 cells,
XTT cell proliferation assay was used. Growth of TXNDC5 knockdown cells was
followed over a period of 5 days. The results show an observable decrease in the growth
of downregulated TXNDC5 cells compared to the control cells (Figure 3.22). To
characterize the role of TXNDC5 in malignant transformation of lung cancer cells,
anchorage independent colony formation assay was used. In which the ability of
TXNDC5 to promote cell growth independent of a solid surface was tested. The results
show that depletion of TXNDC5 caused inhibition of colony formation. Besides,
counterpart overexpression of TXNDC5 promoted colony formation. These results show
expression of TXNDC5 is vital to stimulate tumor growth in A549 lung adenocarcinoma
cells in vitro (Figure 3.23). To study role of TXNDC5 in migratory characteristics of lung
cancer, wound healing Assay was employed. The wound generated in a monolayer of
A549 cells was followed over a period of 3 days. The migratory characteristics of cells to
heal the wound imitate in vivo cell migration. The images of the cells were taken each
day. The wound remaining in ShTXNDC5 cells was nearly 20% more than that of the
control ShNT, in which the gap was completely filled by 3 days. These results show
TXNDC5 to stimulate migratory characteristics of lung cancer cell (Figure 3.24).
To examine role of TXNDC5 in A549 cells invasiveness, three dimensional tumor
spheroid invasion assays was used. The area covered by outgrowth extended form a
spheroid of ShTXNDC5 and Flag-TXNDC5 cells were measured. The area was
measured after 6 days in a medium supplemented with EGF. The results show no
significant different in the distance traveled by cells when TXNDC5 protein expression
was manipulated (Figure 3.25). To study role of TXNDC5 in tumor formation in vivo,
A549 cells were injected in the tail of mice. Immunohistochemistry staining for TXNDC5
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shows formation of multiple tumor nodules in the lung. The result shows presence of cell
aggregates with high TXNDC5 protein expression away from the nodules, possibly
detached and migrated from the nearby nodules (Figure 3.26).
To investigate role of TXNDC5 in MAPK signaling, ShTXNDC5 and FlagTXNDC5 cells were treated with EGF (100ng/ml) for different time points after serum
starvation. Then phosphorylation of each c-jun, AKT, ERK1/2 proteins were measured,
that are activated by Srx-PrxIV signaling. The Western blot results show TXNDC5
knockdown to induce phosphorylation of AKT and ERK1/2. This result was further
supported by opposing effects observed in TXNDC5 overexpressed A549 cells (Figure
3.27). Suggesting possible role of TXNDC5 in modulating protein phosphorylation in lung
cancer cells.

Figure 3.22. A549 proliferative rate decreases with TXNDC5 depletion. Cell proliferation
assay in TXNDC5 knockdown A549 cells measured by XTT assay over a period 5 days
(Mean ± SEM).
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A.

B.

Figure 3.23.

TXNDC5 increases anchorage independent colony formation. A) A549

ShTXNDC5 and Flag-TXNDC5 cells followed for a period of 30 days in soft agar
medium. B) Quantification of number of colonies larger than 50μm in diameter.
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A.

B.

Figure 3.24 TXNDC5 enhances the migration of cancer cells A) One directional cells
migration in TXNDC5 knockdown A549 cells. B) Quantification of gap remaining
between the wounded cells in A (Mean±SEM).
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A.

B.

Figure 3.25. TXNDC5 does not demonstrate invasive behavior in A549 cells in three
dimensional tumor spheroid assay. A) A549 cells spheroids treated with epidermal
growth factor for 6 days (200ng/ml) K) Quantitative analysis of area covered by spheroid
outgrowths in A.
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Figure 3.26. TXNDC5 enhances tumor migration and metastatic in vivo. A549 cells
injected in the tail of mice, immunohistochemistry staining for TXNDC5 shows formation
of multiple of tumor nodules in the lung. Zoom in view of the same slide, shows presence
of aggregates of the cells in other locations, possibly detached and migrated from the
nearby nodules.

92

A.
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B.

C.

D.

E.

Figure 3.27. TXNDC5 depletion increase AKT and ERK1/2 phosphorylation in A549 cells.
A) Western blot of TXNDC5 depleted (ShTXNDC5) and TXNDC5 overexpressed (FlagTXNDC5) cells treated for different durations with 100ng/ml epidermal growth factor
(EGF). B and C) Quantification of the intensity of phosphorylated ERK1/2 (p-ERK1/2) band
after normalization for total ERK1/2 in ShTXNDC5 and Flag-TXNDC5 cells, respectively.
D and E) Quantification of the intensity of phosphorylated AKT (p-AKT) band after
normalization with total AKT in ShTXNDC5 and Flag-TXNDC5 cells, respectively.
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3.1.11. PDIA6 promotes tumorigenesis in lung cancer
For investigate the role of PDIA6 in promoting the growth of lung cancer cells,
growth of PDIA6 knockdown cells were followed over a period of 5 days. The result
shows a noticeable decrease in the growth rate of A549 cells when PDIA6 was
downregulated (Figure 3.28). To study the role of PDIA6 in anchorage independent
colony formation in vitro, the cells ability to form colonies away from a solid surface over
a period of 30 days was measured. The results show a significant decrease in the
number of colonies formed in PDIA6 deficient cells. In contrast, a substantial increase in
colony formation was observed in Flag-PDIA6 cells, signifying PDIA6 role in stimulating
tumor growth (Figure 3.29). To study the role of PDIA6 in migratory characteristics of
lung cancer, wound healing Assay was employed. The wound generated in a monolayer
of A549 cells was followed over a period of 3 days. The images of the cells were taken
each day. The wound remaining in ShPDIA6 cells was nearly 30% more than that of the
control ShNT, in which the gap was completely filled by 3 days (Figure 3.30). These
results show PDIA6 to stimulate migratory characteristics in lung cancer cell.
To examine PDIA6 role in cancer invasiveness, three dimensional tumor
spheroid invasion assays was employed. In which the area covered by spheroid
outgrowths of ShPDIA6 and Flag- PDIA6 cells were measured. The spheroids were
treated with a medium supplemented with EGF for 6 days. The results show no
significant differences in the distance traveled by the cells when PDIA6 protein
expression was manipulated (Figure 3.31). The phosphokinase signaling experiment
shows that knockdown of PDIA6 improved phosphorylation of each c-jun, AKT, ERK1/2
proteins. This result was further supported by opposing effect observed in PDIA6
overexpressed A549 cells measured under same treatment conditions (Figure 3.32).
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Presenting a possible role of PDIA6 in regulating phosphorylation pathways in lung
cancer cells.

Figure 3.28 PDIA6 depletion reduces A549 proliferation rate. Cell proliferation assay in
PDIA6 knockdown A549 cells, measured by XTT assay over a period of 5 days (Mean ±
SEM).
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A.

B.

Figure 3.29

PDIA6 increases anchorage independent colony formation. A) A549

ShPDIA6 and Flag-PDIA6 cells followed for a period of 30 days in soft agar medium. B)
Quantification of number of colonies larger than 50μm in diameter.
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A.

B.

Figure 3.30 PDIA6 depletion lowers cancer cells migration. A) One directional cells
migration in PDIA6 knockdown A549 cells. B) Quantification of gap remaining between
the wounded cells in A (Mean±SEM).
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B.

Figure 3.31 PDIA6 does not demonstrate invasive behavior in A549 cells in three
dimensional tumor spheroid assay. A) A549 spheroids treated with epidermal growth
factor for 6 days (200ng/ml) K) Quantitative analysis of area covered by spheroid
outgrowths in A.
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G.

101

Figure 3.32. PDIA6 depletion increases c-jun, AKT, and ERK1/2 phosphorylation in A549
cells. A) Western blot of PDIA6 depleted (ShPDIA6) and PDIA6 overexpressed (FlagPDIA6) cells treated for different durations with 100ng/ml epidermal growth factor (EGF).
B and C) Quantification of the intensity of phosphorylated c- jun (p-c-jun) band after
normalization for total c-jun in ShPDIA6 and Flag- PDIA6 cells, respectively. D and E)
Quantification of the intensity of phosphorylated ERK1/2 (p-ERK1/2) band after
normalization for total ERK1/2 in ShPDIA6 and Flag- PDIA6 cells, respectively. F and G)
Quantification of the intensity of phosphorylated AKT (p-AKT) band after normalization
for total AKT in ShPDIA6 and Flag- PDIA6 cells, respectively.
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3.2 Discussion
Under oxidative stress conditions, Srx acts to subdue protein folding in the ER
of lung cancer cells. Srx modulates UPR sensor activities in response to accumulation
of misfolded proteins, in particular activity of XBP-1 transcription factor and GRP78.
TXNDC5 and PDIA6 participate in oxidative protein folding. TXNDC5 delays activation
of spliced XBP-1 transcription factor and it is needed to promote GRP78 proteins
expression during ER stress. In addition both TXNDC5 and PDIA6 promote oncogenic
phenotypes in lung cancer in signaling mechanisms different than that of Srx.
As it was previously reported, TXNDC5 and PDIA6 are involved in rapid
oxidative folding of protein substrates (Sato et al., 2013; Kojima et al., 2013). This rapid
folding can introduce abnormal disulfide bonds in the client proteins (Marciniak et al.,
2004; Jessop et al., 2009). Therefore, other PDI family members, for instance, PDIA1
proofreads and amends the incorrect disulfide bonds generated by TXNDC5 and
PDIA6 (Sato et. al, 2013). Hence, it is possible that Srx interacts with the PDI members
to decelerate their contribution to rapid oxidative folding; consequently Srx prevents
accumulation of misfolded proteins. This inference is substantiated by the results of
intracellular refolding assay, in which rapid increases in the luciferase activity was
detected in A549 and H226 Srx knockdown cells after acute H2O2 exposure.
Furthermore, PrxIV-TXNDC5/PDIA6 complexes are previously described to participate
in oxidative substrate folding in Hela cells (Sato et al., 2013; Jessop et al., 2009;
Meunier et al., 2002). In this study, the results support involvement of TXNDC5, PDIA6
in promoting oxidative protein folding in lung cancer. Significant decreases in luciferase
activities detected in each of TXNDC5, PDIA6 or PrxIV knockdown A549 and H2030
cells after acute exposure to H2O2 treatment.

Furthermore, TXNDC5 contributes to

chaperone activities, represented by its role in preventing heat stress-induced protein
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aggregates. In contrast, PDIA6 does not contribute to resolving heat-induced protein
aggregates.
In general, protein folding is enhanced under oxidative stress conditions
(Bhandary et al., 2013). The chaperone activities of PDIs can be regulated by the
redox status. Under stress conditions, the second thioredoxin-like fold is oxidized
triggering a conformational change in the structure of PDIA1 protein. Consequently, the
shielded hydrophobic amino acids, that are involved chaperone activity of PDIA1, are
exposed (Wang et al., 2012). Thus, the oxidoreductase activity of PDIA1 can be
coupled with substrate folding (Wang et al., 2012). It has been reported previously that
the reduced forms of TXNDC5 and PDIA6 enhance the fidelity of PrxIV in oxidative
protein folding. PrxIV has preferences to bind to and oxidize TXNDC5 and PDIA6 than
other PDI members. TXNDC5 and PDIA6 function as a catalyst for Ero1a and PrxIV
substrate folding pathways (Sato et al., 2013). However, overoxidation can introduce
abnormal disulfide bonds in the protein substrates (Marciniak et al., 2004; Jessop et
al., 2009). Therefore, we propose that Srx modulates protein folding in lung cancer
cells, by orchestrating the PDIs function during oxidative stress. The D1 domain of
TXNDC5 and PDIA6, to which Srx binds, might be mechanistically responsible for the
PDIs involvement the chaperone activity. However, further studies are needed to test
this assumption.
Srx is implicated in attenuating TXNDC5 oxidative folding activity; in turn,
TXNDC5 facilitates presence of Srx in the ER. The results of this study demonstrate a
significant decrease in Srx protein levels in the ER following knockdown of TXNDC5 in
A549 cells. In previous studies, the role of TXNDC5 as stabilizing chaperone has been
observed in prostate cancer as well. TXNDC5 stabilizes dimeric form of the androgen
receptor (AR), to protect AR from degradation. TXNDC5 facilitates AR binding to its
ligands and plays a role in AR translocation to the nucleus (Wang et al., 2015). Also,
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knockdown of TXNDC5 in Hela cells increased the availability of AdipoRI receptor on
the plasma membrane; Therefore, TXNDC5 is believed to participate in AdipoR1
retention in the ER. And it may function as an adaptor in AdipoR1 signaling (Charlton
et al., 2010).
To date, no studies are available regarding TXNDC5 transcriptional
regulation in lung cancer cells, and its role ER stress. However, orphan nuclear
receptor NR4A1 is reported to participate in sustaining ER stress in pancreatic cancer
through upregulation of TXNDC5 at transcriptional levels. TXNDC5 upregulation
causes decrease in pro-apoptotic CHOP activities (Lee et al., 2014). In this study,
TXNDC5, PDIA6, or Srx deficient lung cancer cells were more sensitized to
proliferation inhibition induced by tunicamycin than their control cells.

TXNDC5

knockdown cells were more prone to XBP-1 splicing after tunicamycin treatment
compared to the control cells. Decrease in Srx levels reduced spliced XBP-1 levels in
the nuclear fraction. Also, TXNDC5 and Srx knockdown cells expressed less GRP78
proteins compared to the control cells. Spliced XBP-1 is one of the major components
in UPR adaptive phase. Spliced XBP-1 codes for upregulation of chaperones that
correct unfolded/misfolded proteins in the ER. Spliced XBP-1 also codes for
transcribing ERAD pathway to degrade the terminally misfolded proteins. Moreover,
spliced XBP-1 codes for transcription of GRP78 that sequesters and corrects the
folding of protein aggregates in the ER (Fu et al. 2008; Yan et al. 2015; Clarke et al.,
2015). XBP-1 splicing also activates cyclin A1 related activities that is one of the major
components in promoting cell cycle (Yan et al., 2015). Taken together, we concluded
that each of TXNDC5 and Srx contribute to cell response to ER stress in lung cancer
through modulation of XBP-1 signaling pathway. However, more studies are required
to recognize possible Srx/ TXNDC5 interaction with XBP-1 in lung cancer.
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TXNDC5, similar to Srx, is involved in enhancing oncogenic phenotypes of cell
proliferation, anchorage independent colony formation, and one directional cell
migration in cell lines and metastasis in mouse models. Nevertheless, the signaling
mechanism does not recapitulate that of Srx. Srx interaction with PrxIV forms an axis
that contributes to promoting cancer through modulating MAPK/AP-1/MMP9 signaling
at MEK activation level. Knockdown of Srx results in insufficient activation of CREB,
AP-1, and MAPK signaling (Wei et al., 2011). Whereas the data in this study indicate
TXNDC5 deficient cells to have more activation of MAPK through ERK1/2 and AKT
activation. Meanwhile, the activation level of c-Jun does not change. This finding was
further supported by opposite effect observed in TXNDC5 overexpressed A549 cells.
The increase in Adiponectin-stimulated AMPK phosphorylation with TXNDC5
knockdown was reported previously in Hela cells. In which knockdown of TXNDC5
increases AdipoR1 availability for signaling on the cell surface (Charlton et al., 2010).
Hence, TXNDC5 depletion might cause a release of signaling molecules that activates
phosphorylation of ERK1/2 and AKT.
PDIA6 is one of the least studied PDI members in lung cancer. The results
show PDIA6 promotes oncogenic phenotypes of cell proliferation, anchorage
independent colony formation, and one directional cell migration. But similar to
TXNDC5, the signaling in PDIA6 knockdown A549 cells does not repeat that of
signaling in Srx depleted cells. Significant increase in phosphorylation of c-Jun, ERK1/2
and AKT was observed in PDIA6 deficient cells. While in overexpressed PDIA6 cells,
phosphorylation of these proteins was significantly reduced. Further study is required
to identify proteins that modulate TXNDC5 and PDIA6 role in MAPK signaling in lung
cancer.
In breast cancer, ErbB2 was activated with overexpression of PDIA6. PDIA6
was associated with increased cells migration, invasion, and in vivo metastasis. At the
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same time, ErbB2 was determined to be required for the tumorigenic properties of
PDIA6 in MCF7 and MDA-MB-436 cells (Gumireddy et al., 2007). It is possible that
PDIA6 modulates the release of these proteins in the secretory pathway. In fact, most
of the studies on PDIA6 show this protein to function outside the ER. PDIA6 has been
associated with reduction and isomerization reactions on the cell surface. Fractionation
of platelet plasma membrane revealed PDIA6 recruitment to the cell surface in
response to platelet activation.

PDIA6 interacts with integrin αIIbβ3. It has been

associated with platelet aggregation, fibronectin binding, and P-selectin exposure
(Jordan et al., 2005). PDIA6 is believed to exert a thiol isomerase activity when it binds
to the β3 subunit of integrin. This isomerase activity changes the conformation of
αIIbβ3 causing its activation (Jordan et al., 2005). Also, PDIA6 is reported to form a
complex with PDIA1, PDIA4, and GRP78 at the cytosolic face of ER thereby blocking
translocation of prion form ER to the cytosol via the Sec61p site (Stockton et al., 2003).
Furthermore, PDIA6 has been associated with ERAD pathway in the NIT-1 pancreatic
beta cell line. Where PDIA6 was believed to reduce disulfide bonds in misfolded proinsulin proteins in the preparation of its translocation from the ER to the cytosol for
degradation (Gorasia et al., 2016). ERjd5 and PDIA1 are associated with reducing
protein substrates in the ER before directing the substrate to ERAD pathway. For
instance, Cholera toxin chain A and α1-antitrypsin are unfolded by of PDIA1 reductase
activities (Tsae et al., 2001) and ERdj5 (Ushioda et al., 2008), respectively. Because
Srx is well documented to reduce overoxidized 2-Prxs. Therefore, it is possible for Srx
to modulate reduction of PDIA6 in compartments not limited to the ER.
In this chapter, we elucidated the functional significance of Srx, TXNDC5, and
PDIA6 in the tumorigenesis of lung cancer cells. TXNDC5 contribute to chaperone
activities and it is required for Srx retention in the ER. It participates, along with Srx, in
the process of substrate refolding in response to the presence of misfolded protein
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aggregates. Both PDI members, TXNDC5, and PDIA6, increase protein folding under
acute oxidative stress conditions, whereas Srx suppresses protein folding under same
treatment conditions. TXNDC5 modulates UPR sensor activation in response to ER
stress. It delays XBP-1 splicing. Possibly to prevent arrest of protein synthesis and
activation of pro-apoptotic pathways in cancer cells. Whereas Srx may contribute to
modulating splicing of XBP-1, and GRP78 protein expressions in response to ER
stress. Maintaining ER homeostasis can be among many pathways by which Srx,
TXNDC5, and PDIA6 promote cancer development. Since Srx and its interacting
proteins are found to participate in tumorigenesis of lung cancer cells.
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DISCUSSION AND FUTURE DIRECTION

This dissertation explains the role of Srx interacting proteins in lung cancer
development. Srx interacts with redox sensitive thioredoxin-like folds in each of TXNDC5
and PDIA6 in the ER of lung cancer cells. TXNDC5 and PDIA6 engage in nascent
protein folding in the ER. The PDIs involvement in chaperone activity is enhanced under
oxidative stress conditions, whereas Srx has an inhibitory effect on oxidative protein
folding. TXNDC5 maintains Srx localization to the ER. Meanwhile, Srx can bind to
TXNDC5 and PDIA6, perhaps, to regulate their participation in the mechanism of protein
folding, to prevent the formation of oxidative stress induced protein aggregates. Both
TXNDC5 and Srx play important roles in XBP-1 activation regulation.
Srx knockdown initiates ER stress and UPR activation, as indicated by the
change in GRP78 protein expression and XBP-1 splicing. The spliced mRNA of XBP-1
codes for a transcription factor that in turn codes for ER chaperone GRP78 expression
and PDIA6. GRP78 is implicated in several ER functions, including folding, assembly
and degradation of proteins. It is also an important component in UPR sensor activation
and ER Ca+2 binding (Li & Lee, 2006). In cancer, GRP78 has been associated with
tumor growth and drug resistance (Yan et al., 2015). In lung cancer, GRP78 is
upregulated, and it has been related to promoting migration and invasion of tumor cells
(Ma et al., 2015;Yu et al., 2016). Treatment of downregulated TXNDC5 lung cancer cells
with tunicamycin triggered a significant increase in XBP-1 splicing at early doses of
treatment compared to control cells. Event though, the overall sXBP-1 levels reduced in
the nuclear fraction. Meanwhile TXNDC5 knockdown decreased expression of GRP78.
PDIA6 gene exhibits self-regulation during ER stress. It regulates the duration of
IRE1α phosphorylation in mouse fibroblast cells as well as C. elegans. PDIA6 reduces
disulfide bonds in the activated IRE1α oligomer resulting in IRE1α dephosphorylation.
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Prolonged IRE1α activation causes an increase in XBP-1 splicing and activation of
apoptotic pathways (Eletto et al., 2014). Meanwhile, XBP-1 splicing regulates PDIA6
expression. Spliced XBP-1 can bind to ERSE elements in the promoter region of PDIA6
to induce PDIA6 expression during UPR activation (Lee et al., 2003; Galligan &
Petersen, 2012).

Moreover, cleaved ATF6 was found to bind to ERSE element in

ischemic cardiac myocytes of mouse providing protection against ER stress (Vekich et
al., 2013). Therefore, PDIA6 functions to prevent apoptosis through termination of
prolonged UPR activation (Eletto et al., 2014). PDIA6 is shown to prevent RIPK1
activation, which is involved in necrotic signaling pathways in lung cancer. PDIA6
downregulated cells show decreased GRP78 protein expression (Tufo el al, 2014). In
fact, PDIA6 is known to cooperate with specificity toward GRP78 to form a non-covalent
interaction (Jessop et al., 2009). Therefore, it is plausible to propose that TXNDC5,
similar to PDIA6, is involved in the termination of XBP-1 to prevent their over-activation,
which triggers UPR induced cell death pathways. As it is shown in our results, TXNDC5
deficient cells are more sensitive to early XBP-1 splicing compared to the control cells.
Splicing of XBP-1 is also associated with cyclin D1 activation that promotes cell cycle
progression (Yan et al., 2015; He et al., 2011; Zucal et al., 2015; Xie et al., 2015). This
may explain inhibition of growth in Srx and TXNDC5 deficient cells in response to
tunicamycin treatment. Based on these foundations we propose TXNDC5 to negatively
regulate XBP-1 splicing, possibly through termination of transiently activated IRE1
signaling. And that Srx regulates IRE1 signaling pathway activation. Our data suggests
that Srx contributes to UPR through regulation of XBP-1 splicing, and GRP78 expression
in response to ER stress.
Moreover, TXNDC5 and PDIA6 are oncogenes that participate in promoting
tumorigenesis in lung cancer cells. The results show that both proteins promote cell
proliferation, anchorage independent colony formation, and cell migration. It is possible
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that these two proteins participate in the oncogenesis of cancer cells through regulating
ER quality control system in response to stress conditions.

In summary, in this study, we examined the function of Srx in lung cancer
cells, through its interacting TXNDC5, and PDIA6 proteins. TXNDC5 and PDIA6 are
oncogenes that contribute to promoting cells division, colony formation and cell
migration. TXNDC5 contributes to modulating ERK1/2 and AKT signaling, while PDIA6
modulates phosphorylation of c-Jun, ERK1/2, and AKT proteins. Srx interacts with the
redox-sensitive thioredoxin-like fold of TXNDC5 and PDIA6 in response to oxidative
stress. The N-terminal (D1) of TXNDC5 or PDIA6 acts as the main platforms for this
interaction. Srx is found to co-localize with TXNDC5 and PDIA6 in the ER, to modulate
their role in oxidative protein folding. Srx-PDIs interaction is vital in preventing protein
misfolding and UPR activation. Perhaps to avoid activation of UPR mediated cells death.
Therefore, we suggest Srx-TXNDC5/PDIA6 axis to be a valuable target for future
development of therapeutic methods in lung cancer.

A better understanding of function of Srx, TXNDC5 or PDIA6 in UPR of lung
cancer can present a unique opportunity for development of therapeutic targets.
Therefore, in the future it would of interest to study molecular function of Srx and its
interacting proteins in activation of the other UPR sensors in lung cancer, ATF6 and
PERK sensors. Because Srx interaction with the PDIs mainly occurs through the Nterminal thioredoxin like fold, it would be of interest to study the role of this redox
sensitive domain in the PDIs chaperone activities, and its implication to UPR sensors
activation. Then This Srx-PDIs axis can be utilized for development of therapeutic drugs
to sensitize cancer cells to UPR induced growth inhibition and apoptosis. Beside, PDIs
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role in Nrf2 and MAPK signaling can be further investigated in the future to understand
their potential role in transcriptional regulation of Srx in lung cancer.
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Figure 3.33. Proposed model for Srx-TXNDC5/PDIA6 interaction under oxidative

stress conditions. Srx interacts with the N-terminal thioredoxin like fold in
TXNDC5 and PDIA6. TXNDC5 and PDIA6, along with Ero1 and PrxIV participate
in oxidative protein folding. In contrary, Srx has an inhibitory effect on oxidative
protein folding. Srx-TXNDC5 interaction is enhanced under oxidative stress
conditions. TXNDC5 facilitates Srx retention in the ER compartment, to sustain
homeostasis of oxidative protein folding in lung cancer cells.
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Figure 3.34. Proposed model for role of Srx and TXNDC5 in UPR activation. Srx
contributes to the activation of UPR adaptive response pathway via activation of spliced
XBP-1 (sXBP-1) transcription factor in the nucleus fraction, under ER stress conditions.
TXNDC5 participates in the process of correctly folding unfolded/misfolded proteins in
the ER. Thus TXNDC5 delays activation of sXBP-1 transcription factor. Both Srx and
TXNDC5 activities contribute to boosting GRP78 protein expression during tunicamycin
induced ER stress.
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APPENDEX
LIST OF ABBERIVIATIONS
Adipor1:

Adiponectin Receptor 1

AP-1:

Activator Protein-1

AR:

Androgen Receptor

ATF6:

Activating Transcription Factor 6

CHOP:

C/EBP Homologous Protein

D:

Thioredoxin like domain (CGHC)

ERAD:

Endoplasmic Reticulum-Associated Protein Degradation

ERK1/2

Extracellular Signal-Regulated Kinase 1/2

ERO1:

Endoplasmic Reticulum oxidoreductin-1

GRP78:

Glucose-Regulated Protein, 78kDa

IRE1

Inositol-Requiring Enzyme 1

MAPK:

Mitogen-Activated Protein Kinase

Nrf2:

Nuclear Factor (Erythroid-Derived 2)-Like 2

PDI:

Protein Disulfide Isomerase

PDIA1:

Protein Disulfide Isomerase Family A, Member 1

PDIA6:

Protein Disulfide Isomerase Family A, Member 6

PERK:

PRKR-Like Endoplasmic Reticulum Kinase

Prx:

Peroxiredoxin

SRX:

Sulfiredoxin

TXNDC5:

Thioredoxin Domain Containing Protein 5

UPR:

Unfolded Protein Response

XBP-1:

X-Box Binding Protein 1
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pcDNA3.1 myc-His A Plasmid Map

TXNDC5 cDNA was inserted to pcDNA3.1 myc-His A Plasmid using XhoI and XbaI
restriction sites. PDIA6 gene was inserted using Hind III and XhoI restriction sites. And
Srx gene was inserted using BamHI and EcoRI restriction sites. (Plasmid image:
SnapGene viewer).
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p3xFLAG-CMV™-14 Plasmid Map

To tag cDNA of each of TXNDC5 and PDIA6 with Flag sequence, the cDNA of these
gene were subcloned from pcDNA3.1 myc-His A to p3xFLAG-CMV-14 vector. For
TXNDC5-Flag NotI and XbaI restriction sites were used while for PDIA6 HindIII and Xbal
enzymes were used. (Plasmid image: SnapGene viewer)
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pLVX-IRES-Puro Plasmid Map

The cDNA of each of TXNDC5 and PDAI6 tagged at the C-terminal with Flag
sequence were subcloned from p3xFLAG-CMV-14 vector to pLVX-IRES-Puro vector.
SalI and BstBI restrictions sites were used to cut the genes from p3xFLAG-CMV -14
vector and they were inserted to XhoI and BstBI sites in pLVX-IRES-Puro vectors for
both genes. (Plasmid image: SnapGene viewer)
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Based on the homology modeling and results of structure prediction from I-TASSAR and
Z-doc interaction prediction software, the following constructs were used for investigating
Srx TXNDC5/PDIA6 interactions:

C- terminal Flag tagged TXNDC5 cDNA showing thioredoxin like domains (underlined),
thioredoxin like folds (yellow), and Flag tag sequence (lower case nucleotides at the Cterminus):
ATGCCCGCGCGCCCAGGACGCCTCCTCCCGCTGCTGGCCCGGCCGGCGGCCCTG
ACTGCGCTGCTGCTGCTGCTGCTGGGCCATGGCGGCGGCGGGCGCTGGGGCGC
CCGGGCCCAGGAGGCGGCGGCGGCGGCGGCGGACGGGCCCCCCGCGGCAGAC
GGCGAGGACGGACAGGACCCGCACAGCAAGCACCTGTACACGGCCGACATGTTC
ACGCACGGGATCCAGAGCGCCGCGCACTTCGTCATGTTCTTCGCGCCCTGGTGTG
GACACTGCCAGCGGCTGCAGCCGACTTGGAATGACCTGGGAGACAAATACAACAG
CATGGAAGATGCCAAAGTCTATGTGGCTAAAGTGGACTGCACGGCCCACTCCGAC
GTGTGCTCCGCCCAGGGGGTGCGAGGATACCCCACCTTAAAGCTTTTCAAGCCAG
GCCAAGAAGCTGTGAAGTACCAGGGTCCTCGGGACTTCCAGACACTGGAAAACTG
GATGCTGCAGACACTGAACGAGGAGCCAGTGACACCAGAGCCGGAAGTGGAACC
GCCCAGTGCCCCCGAGCTCAAGCAAGGGCTGTATGAGCTCTCAGCAAGCAACTTT
GAGCTGCACGTTGCACAAGGCGACCACTTTATCAAGTTCTTCGCTCCGTGGTGTGG
TCACTGCAAAGCCCTGGCTCCAACCTGGGAGCAGCTGGCTCTGGGCCTTGAACAT
TCCGAAACTGTCAAGATTGGCAAGGTTGATTGTACACAGCACTATGAACTCTGCTC
CGGAAACCAGGTTCGTGGCTATCCCACTCTTCTCTGGTTCCGAGATGGGAAAAAGG
TGGATCAGTACAAGGGAAAGCGGGATTTGGAGTCACTGAGGGAGTACGTGGAGTC
GCAGCTGCAGCGCACAGAGACTGGAGCGACGGAGACCGTCACGCCCTCAGAGGC
CCCGGTGCTGGCAGCTGAGCCCGAGGCTGACAAGGGCACTGTGTTGGCACTCACT
GAAAATAACTTCGATGACACCATTGCAGAAGGAATAACCTTCATCAAGTTTTATGCT
CCATGGTGTGGTCATTGTAAGACTCTGGCTCCTACTTGGGAGGAACTCTCTAAAAA
GGAATTCCCTGGTCTGGCGGGGGTCAAGATCGCCGAAGTAGACTGCACTGCTGAA
CGGAATATCTGCAGCAAGTATTCGGTACGAGGCTACCCCACGTTATTGCTTTTCCG
AGGAGGGAAGAAAGTCAGTGAGCACAGTGGAGGCAGAGACCTTGACTCGTTACAC
CGCTTTGTCCTGAGCCAAGCGAAAGACGAACTTtctagaggatcccgggctgactacaaagaccat
gacggtgattataaagatcatgacatcgactacaaggatgacgatgacaag
Translation of TXNDC5 sequence:
MPARPGRLLPLLARPAALTALLLLLLGHGGGGRWGARAQEAAAAAADGPPAADGEDG
QDPHSKHLYTADMFTHGIQSAAHFVMFFAPWCGHCQRLQPTWNDLGDKYNSMEDAK
VYVAKVDCTAHSDVCSAQGVRGYPTLKLFKPGQEAVKYQGPRDFQTLENWMLQTLNE
EPVTPEPEVEPPSAPELKQGLYELSASNFELHVAQGDHFIKFFAPWCGHCKALAPTWE
QLALGLEHSETVKIGKVDCTQHYELCSGNQVRGYPTLLWFRDGKKVDQYKGKRDLESL
REYVESQLQRTETGATETVTPSEAPVLAAEPEADKGTVLALTENNFDDTIAEGITFIKFY
APWCGHCKTLAPTWEELSKKEFPGLAGVKIAEVDCTAERNICSKYSVRGYPTLLLFRG
GKKVSEHSGGRDLDSLHRFVLSQAKDEL
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C- terminal Flag tagged PDIA6 cDNA showing thioredoxin like domains (underlined),
thioredoxin like folds (yellow), and Flag tag sequence (lower case nucleotides at the Cterminus):

ATGGCTCTCCTGGTGCTCGGTCTGGTGAGCTGTACCTTCTTTCTGGCAGTGAATGG
TCTGTATTCCTCTAGTGATGATGTGATCGAATTAACTCCATCGAATTTCAACCGAGA
AGTTATTCAGAGTGATAGTTTGTGGCTTGTAGAATTCTATGCTCCATGGTGTGGTCA
CTGTCAAAGATTAACACCAGAATGGAAGAAAGCAGCAACTGCATTAAAAGATGTTGT
CAAAGTTGGTGCAGTTGATGCAGATAAGCATCATTCCCTAGGAGGTCAGTATGGTG
TTCAGGGATTTCCTACCATTAAGATTTTTGGATCCAACAAAAACAGACCAGAAGATT
ACCAAGGTGGCAGAACTGGTGAAGCCATTGTAGATGCTGCGCTGAGTGCTCTGCG
CCAGCTCGTGAAGGATCGCCTCGGGGGACGGAGCGGAGGATACAGTTCTGGAAAA
CAAGGCAGAAGTGATAGTTCAAGTAAGAAGGATGTGATTGAGCTGACAGACGACAG
CTTTGATAAGAATGTTCTGGACAGTGAAGATGTTTGGATGGTTGAGTTCTATGCTCC
TTGGTGTGGACACTGCAAAAACCTAGAGCCAGAGTGGGCTGCCGCAGCTTCAGAA
GTAAAAGAGCAGACGAAAGGAAAAGTGAAACTGGCAGCTGTGGATGCTACAGTCAA
TCAGGTTCTGGCCTCCCGATACGGGATTAGAGGATTTCCTACAATCAAGATATTTCA
GAAAGGCGAGTCTCCTGTGGATTATGACGGTGGGCGGACAAGATCCGACATCGTG
TCCCGGGCCCTTGATTTGTTTTCTGATAACGCCCCACCTCCTGAGCTGCTTGAGAT
TATCAACGAGGACATTGCCAAGAGGACGTGTGAGGAGCACCAGCTCTGTGTTGTG
GCTGTGCTGCCCCATATCCTTGATACTGGAGCTGCAGGCAGAAATTCTTATCTGGA
AGTTCTTCTGAAGTTGGCAGACAAATACAAAAAGAAAATGTGGGGGTGGCTGTGGA
CAGAAGCTGGAGCCCAGTCTGAACTTGAGACCGCGTTGGGGATTGGAGGGTTTGG
GTACCCCGCCATGGCCGCCATCAATGCACGCAAGATGAAATTTGCTCTGCTAAAAG
GCTCCTTCAGTGAGCAAGGCATCAACGAGTTTCTCAGGGAGCTCTCTTTTGGGCGT
GGCTCCACGGCACCTGTAGGAGGCGGGGCTTTCCCTACCATCGTTGAGAGAGAGC
CTTGGGACGGCAGGGATGGCGAGCTTCCCGTGGAGGATGACATTGACCTCAGTGA
TGTGGAGCTTGATGACTTAGGGAAAGATGAGTTGCTCGAGtctagaggatcccgggctgacta
caaagaccatgacggtgattataaagatcatgacatcgactacaaggatgacgatgacaagTAGTGATCC

Translation of PDIA6 sequence:
MALLVLGLVSCTFFLAVNGLYSSSDDVIELTPSNFNREVIQSDSLWLVEFYAPWCGHCQ
RLTPEWKKAATALKDVVKVGAVDADKHHSLGGQYGVQGFPTIKIFGSNKNRPEDYQG
GRTGEAIVDAALSALRQLVKDRLGGRSGGYSSGKQGRSDSSSKKDVIELTDDSFDKNV
LDSEDVWMVEFYAPWCGHCKNLEPEWAAAASEVKEQTKGKVKLAAVDATVNQVLAS
RYGIRGFPTIKIFQKGESPVDYDGGRTRSDIVSRALDLFSDNAPPPELLEIINEDIAKRTC
EEHQLCVVAVLPHILDTGAAGRNSYLEVLLKLADKYKKKMWGWLWTEAGAQSELETAL
GIGGFGYPAMAAINARKMKFALLKGSFSEQGINEFLRELSFGRGSTAPVGGGAFPTIVE
REPWDGRDGELPVEDDIDLSDVELDDLGKDEL
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Srx sequence in pcDNA3.1 myc-His A plasmid (Cys99 is shaded with yellow color):
ATGGGGCTGCGTGCAGGAGGAACGCTGGGCAGGGCCGGCGCGGGTCGGGGGGC
GCCCGAGGGGCCCGGGCCGAGCGGCGGCGCGCAGGGCGGCAGCATCCACTCGG
GCCGCATCGCCGCGGTGCACAACGTGCCGCTGAGCGTGCTCATCCGGCCGCTGC
CGTCCGTGTTGGACCCCGCCAAGGTGCAGAGCCTCGTGGACACGATCCGGGAGG
ACCCAGACAGCGTGCCCCCCATCGATGTCCTCTGGATCAAAGGGGCCCAGGGAGG
TGACTACTTCTACTCCTTTGGGGGCTGCCACCGCTACGCGGCCTACCAGCAACTGC
AGCGAGAGACCATCCCCGCCAAGCTTGTCCAGTCCACTCTCTCAGACCTAAGGGT
GTACCTGGGAGCATCCACACCAGACTTGCAGTAG
Translation of Srx sequence:
MGLRAGGTLGRAGAGRGAPEGPGPSGGAQGGSIHSGRIAAVHNVPLSVLIRPLPSVLD
PAKVQSLVDTIREDPDSVPPIDVLWIKGAQGGDYFYSFGGCHRYAAYQQLQRETIPAKL
VQSTLSDLRVYLGASTPDLQ
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